



## National foreword

This British Standard is the UK implementation of ISO 29943-1:2017.

The UK participation in its preparation was entrusted to Technical Committee CH/157, Mechanical contraceptives.

A list of organizations represented on this committee can be obtained on request to its secretary.

This publication does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

© The British Standards Institution 2017  
Published by BSI Standards Limited 2017

ISBN 978 0 580 85628 0

ICS 11.200

**Compliance with a British Standard cannot confer immunity from legal obligations.**

This British Standard was published under the authority of the Standards Policy and Strategy Committee on 31 July 2017.

### Amendments/corrigenda issued since publication

Date	Text affected
<hr/>	

# INTERNATIONAL STANDARD

**ISO**  
**29943-1**

First edition  
2017-07

---

---

## **Condoms — Guidance on clinical studies —**

### **Part 1: Male condoms, clinical function studies based on self-reports**

*Préservatifs — Directives relatives aux études cliniques —*

*Partie 1: Préservatifs masculins — Études fonctionnelles cliniques  
basées sur des auto-déclarations*



Reference number  
ISO 29943-1:2017(E)

© ISO 2017



**COPYRIGHT PROTECTED DOCUMENT**

© ISO 2017, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office  
Ch. de Blandonnet 8 • CP 401  
CH-1214 Vernier, Geneva, Switzerland  
Tel. +41 22 749 01 11  
Fax +41 22 749 09 47  
[copyright@iso.org](mailto:copyright@iso.org)  
[www.iso.org](http://www.iso.org)

<b>Contents</b>		<b>Page</b>
<b>Foreword</b> .....		<b>v</b>
<b>Introduction</b> .....		<b>vi</b>
<b>1</b>	<b>Scope</b> .....	<b>1</b>
<b>2</b>	<b>Normative references</b> .....	<b>1</b>
<b>3</b>	<b>Terms and definitions</b> .....	<b>1</b>
<b>4</b>	<b>Pilot clinical studies</b> .....	<b>2</b>
<b>5</b>	<b>Clinical validation investigation</b> .....	<b>3</b>
5.1	Objectives of clinical validation investigation.....	3
5.2	Outcome measures.....	3
5.3	Study subjects.....	3
5.3.1	General.....	3
5.3.2	Enrolment of study subjects.....	3
5.4	Informed consent.....	5
5.5	Test and control condoms.....	5
5.5.1	General.....	5
5.5.2	Test condom.....	5
5.5.3	Control condom made from natural rubber latex.....	6
5.5.4	Expiration date of control condom.....	6
5.5.5	Storage conditions.....	6
5.5.6	Trial duration exceeds 1 year.....	6
5.5.7	Sampling of control condoms for bench testing.....	6
5.6	Randomization.....	6
5.7	Allocation concealment and study masking.....	7
5.8	Use of additional lubricant.....	7
5.9	Instructions and interactions with study couples.....	7
5.10	Interviews and data collection.....	8
5.10.1	Schedule for interviews and condom distribution.....	8
5.10.2	Enrolment interview.....	8
5.10.3	Individual condom use CRF.....	8
5.10.4	Mid-study CRF, crossover trial.....	9
5.10.5	Compiling data from CRFs.....	9
5.11	Data integrity.....	10
5.11.1	General.....	10
5.11.2	Interactive voice response systems (IVRS).....	10
5.11.3	Mail-in and web-based data reporting.....	10
5.11.4	Web-based data collection systems and additional suggestions.....	11
5.12	Control of distribution chain.....	11
5.13	Analysis of returned condoms.....	12
5.14	Other methodological details.....	12
5.15	Statistical analysis plan.....	12
5.15.1	General.....	12
5.15.2	Primary study hypothesis.....	13
5.15.3	Secondary study hypotheses.....	13
5.15.4	Study design.....	13
5.15.5	Statistical analysis.....	14
5.15.6	Additional statistical comments and concerns.....	14
5.16	Clinical study results: Review and interpretation.....	15
5.16.1	General.....	15
5.16.2	Total clinical failure rates for control condom.....	15
5.16.3	Non-inferiority.....	15
5.16.4	Superiority.....	15
5.16.5	Safety (adverse events).....	15

5.16.6 What happens if one is unable to conclude non-inferiority?..... 16

**Annex A (informative) Formula for power calculation.....17**

**Annex B (informative) Pilot clinical investigation (sample outline).....18**

**Annex C (informative) Time and events schedule for individual study subject (sample) .....20**

**Annex D (informative) CRF — Study entry (sample) .....21**

**Annex E (informative) CRF — Mid-study (sample) .....24**

**Annex F (informative) CRF — Individual condom use (sample).....25**

**Annex G (informative) CRF — Adverse event (sample).....32**

**Annex H (informative) Protocol for evaluation of returned used condoms .....34**

**Bibliography .....41**

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see [www.iso.org/directives](http://www.iso.org/directives)).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see [www.iso.org/patents](http://www.iso.org/patents)).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: [www.iso.org/iso/foreword.html](http://www.iso.org/iso/foreword.html).

This document was prepared by Technical Committee ISO/TC 157, *Non-systemic contraceptives and STI barrier prophylactics*.

A list of all the parts of ISO 29943 can be found on the ISO website.

## Introduction

Male condoms made from natural rubber latex (NRL) have a long history of safety and effectiveness and their performance during use is well established. However, male condoms made from new materials require clinical validation to ensure that their performance during actual use is not inferior to that of NRL condoms. Such clinical validation studies, called clinical function studies, are designed to compare the rates of acute failure event, i.e. breakage or complete slippage. Statistical analysis based on a non-inferiority comparison is employed to help ensure that the difference is not excessive.

This clinical study guidance is intended to help in the design, execution, analysis and interpretation of clinical function studies conducted in accordance with requirements of the ISO 23409 for synthetic male condoms. However, it can also be used with appropriate modifications to evaluate other male condoms with additional claims for improved efficacy or safety (see ISO 4074:2015, Clause 8). In addition to information regarding the clinical validation study, this document provides recommendations on pilot studies and statistical analysis plans. Annexes include previously used case report forms and protocols that can be modified or adapted.

**NOTE** Based on the normative clinical requirement of relevant standards, these studies are designed to recruit participating couples who agree to use the test and control condoms for vaginal intercourse. Such studies can also collect incidental data on condom use during anal sex; however, that is not the primary objective. To satisfy study power requirements, it is critical that sufficient reports are collected on condom use during vaginal intercourse. Study sponsors typically take preventive measures, such as initial screening and consenting of study couples, and obtain agreement that study couples will use condoms this way.

These clinical function studies are not typically designed to directly evaluate condom protection against pregnancy or sexually transmitted infections (STIs).

Finally, it is important to recognize that clinical function studies of condoms are human research studies. Therefore, all persons designing, running and analysing clinical studies of new condoms should be familiar with all relevant standards for research involving human subjects, including ethical considerations. For additional information, refer to ISO 14155.

# Condoms — Guidance on clinical studies —

## Part 1: Male condoms, clinical function studies based on self-reports

### 1 Scope

This document is intended to help in the design, execution, analysis and interpretation of clinical function studies conducted in accordance with the requirements of ISO 23409 for male synthetic condoms.

These clinical studies compare the performance of a new male condom to an established male condom during vaginal intercourse (not anal intercourse). In particular, these studies are designed to assess acute failure events during use (i.e. clinical slippage and clinical breakage).

This document also provides direction on the analysis of data when the study is completed, as well as interpretation of these results by manufacturers and regulatory bodies.

Certain clinical trial elements are not addressed in this document, including compensation, confidentiality of individuals and their records, use of local ethics committees, etc. These and many other clinical trial design issues are covered in greater detail in ISO 14155.

### 2 Normative references

There are no normative references in this document.

### 3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <http://www.iso.org/obp>
- IEC Electropedia: available at <http://www.electropedia.org/>

**NOTE** All of the clinical failure events defined below represents potential vaginal exposure to semen and other penile discharge. Non-clinical failure events do not risk exposure.

#### 3.1 clinical breakage

breakage or tearing of the condom during intercourse or withdrawal from the vagina

Note 1 to entry: This might not be noticed until after inspection of the condom following intercourse.

Note 2 to entry: Any breakages that do not meet the definition of clinical breakage are considered “non-clinical breakage” (e.g. tearing the condom when opening the package).

### 3.2

#### **clinical breakage rate**

number of condoms broken or torn during intercourse or withdrawal divided by the number of condoms used during intercourse

Note 1 to entry: The clinical breakage rate is typically reported as a percentage.

### 3.3

#### **clinical slippage**

condom slipping off completely during intercourse or during withdrawal from the vagina

Note 1 to entry: Sometimes slippage occurs because the user failed to hold onto the condom at the base of the penis during withdrawal and/or because the user delayed withdrawal after sex. These events are considered user failures; record such events as “non-clinical slippage.” Do not count such user failures as clinical slippage events.

Note 2 to entry: If a condom slips off primarily as a result of breakage, do not count that as a slippage event.

### 3.4

#### **clinical slippage rate**

number of condoms that slipped completely off the penis during intercourse or withdrawal divided by the number of condoms used during intercourse

Note 1 to entry: The clinical slippage rate is typically reported as a percentage.

### 3.5

#### **clinical failure event**

*clinical breakage* ([3.1](#)) or *clinical slippage* ([3.3](#))

### 3.6

#### **non-inferiority margin**

$\delta$

statistical term used to identify clinically meaningful differences between products

Note 1 to entry: Differences between product means which are less than  $\delta$  are interpreted as noise inherent in the study while differences between product means which are greater than  $\delta$  are attributed to a meaningful difference between products.

### 3.7

#### **bias**

systematic error caused by a variable not considered in the calculation of results

Note 1 to entry: Three common causes of bias in this type of clinical study are 1) selection bias, where certain types of study subjects are not representative for the outcome being assessed, 2) recall bias, where poor questionnaire design or lengthy time between when condom is used and when the use events are recorded and 3) misclassification, where the outcome of interest (e.g. breakage or slippage) is recorded or assigned erroneously.

Note 2 to entry: The term bias is used in statistics to refer to how far the expected value of a statistic lies from the parameter it is estimating.

## 4 Pilot clinical studies

Validation of a new condom to generally accepted standards requires considerable time, effort and money. Therefore, pilot studies should be done to characterize and quantify the risk in undertaking the necessary larger scale investigation of clinical breakage and slippage. Typically, these pilot studies enrol 35 to 50 couples who use three to five condoms of each type (test and control). Pilot studies are intended to help determine whether the larger clinical validation study is warranted (i.e. are study results promising). Pilot studies can also be used to test questionnaires and other study instruments. Such studies also provide information for assumptions on clinical failure rates in the intended study population as these will influence the calculations of study power and sample size of the larger study. [Annex B](#) contains a sample outline for a pilot clinical study.

### 3.2

#### **clinical breakage rate**

number of condoms broken or torn during intercourse or withdrawal divided by the number of condoms used during intercourse

Note 1 to entry: The clinical breakage rate is typically reported as a percentage.

### 3.3

#### **clinical slippage**

condom slipping off completely during intercourse or during withdrawal from the vagina

Note 1 to entry: Sometimes slippage occurs because the user failed to hold onto the condom at the base of the penis during withdrawal and/or because the user delayed withdrawal after sex. These events are considered user failures; record such events as “non-clinical slippage.” Do not count such user failures as clinical slippage events.

Note 2 to entry: If a condom slips off primarily as a result of breakage, do not count that as a slippage event.

### 3.4

#### **clinical slippage rate**

number of condoms that slipped completely off the penis during intercourse or withdrawal divided by the number of condoms used during intercourse

Note 1 to entry: The clinical slippage rate is typically reported as a percentage.

### 3.5

#### **clinical failure event**

*clinical breakage* ([3.1](#)) or *clinical slippage* ([3.3](#))

### 3.6

#### **non-inferiority margin**

$\delta$

statistical term used to identify clinically meaningful differences between products

Note 1 to entry: Differences between product means which are less than  $\delta$  are interpreted as noise inherent in the study while differences between product means which are greater than  $\delta$  are attributed to a meaningful difference between products.

### 3.7

#### **bias**

systematic error caused by a variable not considered in the calculation of results

Note 1 to entry: Three common causes of bias in this type of clinical study are 1) selection bias, where certain types of study subjects are not representative for the outcome being assessed, 2) recall bias, where poor questionnaire design or lengthy time between when condom is used and when the use events are recorded and 3) misclassification, where the outcome of interest (e.g. breakage or slippage) is recorded or assigned erroneously.

Note 2 to entry: The term bias is used in statistics to refer to how far the expected value of a statistic lies from the parameter it is estimating.

## 4 Pilot clinical studies

Validation of a new condom to generally accepted standards requires considerable time, effort and money. Therefore, pilot studies should be done to characterize and quantify the risk in undertaking the necessary larger scale investigation of clinical breakage and slippage. Typically, these pilot studies enrol 35 to 50 couples who use three to five condoms of each type (test and control). Pilot studies are intended to help determine whether the larger clinical validation study is warranted (i.e. are study results promising). Pilot studies can also be used to test questionnaires and other study instruments. Such studies also provide information for assumptions on clinical failure rates in the intended study population as these will influence the calculations of study power and sample size of the larger study. [Annex B](#) contains a sample outline for a pilot clinical study.

### **5.3.2.1 Inclusion criteria**

The following is a list of recommended criteria for selection of study couples.

- a) mutually monogamous, current relationship  $\geq 3$  months;
- b) already protected from pregnancy, e.g. oral contraceptive, intrauterine device, injectable, patch, male or female sterilization;
- c) 18 years to 45 years of age;
- d) sexually active, sufficient to meet protocol requirements; agree to have penile-vaginal intercourse with frequency sufficient to meet protocol requirements;
- e) agree to use only study condoms during time of participation;
- f) agree not to use drugs or non-study devices that can affect sexual performance;
- g) able to understand instructions for correct use of condoms;
- h) no known sexually transmitted infections including HIV/AIDS;
- i) agree to use only lubricant(s) provided by the study;
- j) agree not to wear any genital piercing jewellery while using study condoms;
- k) willing and capable of following requirements of protocol, including willingness to respond to questions about reproductive and contraceptive history and use of condoms during interviews and on self-administered questionnaires;
- l) available for follow-up.

If self-administered questionnaires are used in the study, the study subjects should have an adequate level of literacy commensurate with the questionnaires.

### **5.3.2.2 Exclusion criteria**

The following is a list of recommended criteria for excluding a couple from the study at the time of entry or at any time during the study.

If either partner is (or becomes) aware that

- a) he/she is allergic or sensitive to the material(s) of the test or control condoms,
- b) female partner is pregnant or desires to become so while participating in study,
- c) subject knowingly has a sexually transmitted infection,
- d) commercial sex workers,
- e) itinerant persons who cannot be able to complete the study, e.g. migrant farm workers,
- f) male partner has known erectile or ejaculatory dysfunction,
- g) either partner is using any medications or preparation applied topically or intravaginally to the genitalia other than that supplied for the study,
- h) either partner is an employee of study sponsor or affiliated with clinical research centre,

it is possible to conduct a condom breakage and slippage study in a population at risk of pregnancy, i.e. not using a back-up contraceptive. In fact, this can be more representative of the target population in the commercial market. However, the risk of pregnancy during the study should be considered, as well as any measures in the protocol to manage that risk. Such a study can be subject to additional requirements from the local regulatory body.

## 5.4 Informed consent

The purpose and requirements of the study should be explained before prospective couples are presented with informed consent forms. Subjects should also be advised that more detailed information about sexual activity will be collected than is typical of most family planning visits. Subjects should be given an opportunity to ask questions about the study and/or the content of the informed consent. Couples should be informed that both partners should agree to participate in the study in order for them to join. If both members of the couple agree to participate, they should each be given a separate informed consent form to sign. All volunteers should provide written informed consent before they are enrolled in the study. All participants should receive a copy of their signed informed consent forms.

Subjects should be informed about the potential for condom failure and the availability of emergency contraception in the event of condom failure (if not otherwise using a highly effective alternate method of contraception).

NOTE Useful information regarding informed consent is available in Reference [11]. Also see Reference [12].

## 5.5 Test and control condoms

### 5.5.1 General

Both control and test condoms should be evaluated according to ISO 16037. This is important because these results are used to establish the specifications of the new condom and to verify that the control condom represents a typical condom already approved for market. When the test condom is synthetic, then sufficient sample sizes should be used to establish baseline properties as specified in ISO 23409.

NOTE ISO 16037 is a test method and not restricted to rubber products.

The protocol for the clinical function study should provide physical description of both test and control condoms, including material, length, lay-flat width, thickness, lubricant formulation and appearance.

### 5.5.2 Test condom

The test condom should meet performance specifications throughout the study.

- a) Test condoms used in the clinical study should be manufactured using the same manufacturing process(es), equipment, specifications and quality assurance procedures as the product to be commercially marketed. Test condoms for the clinical study should be selected from a normal production run.
- b) Test condoms should be selected from a single lot. As stated above, when the test condom is synthetic, the compliance of the lot with the specification should be assessed using the sample plans specified in ISO 23409:2011, Annex B.

If test condoms for the clinical study are selected from more than one lot, then precautions should be taken to ensure that the individual lots comply with the specification and are of a similar age and from a similar period of production, e.g. within 3 months. It is not acceptable to mix samples from lots produced using significantly different processes or equipment.

- c) As specified in ISO 23409:2011, Clause 11, when the test condom is synthetic the airburst properties of test condoms from all lots (preferably only a single lot) should be determined using a sample size of at least 2 000 condoms. Other properties of the condom should be determined and recorded using the principles underlying ISO 16037.
- d) For the purposes of the trial, the test condoms can be packed in non-standard packaging, i.e. showing sequence and randomization allocation without typical brand. However, the packaging should provide the same level of protection to the condom as normal production packaging. If non-standard packaging is used, the manufacturer or the organization responsible for the trial should ensure that the proper labelling information (such as that specified in ISO 23409:2011, 16.2 for synthetic condoms) is made available to the study participants.

NOTE Local regulations can require additional labelling.

### **5.5.3 Control condom made from natural rubber latex**

The control condom selected for the breakage and slippage study should meet the following conditions.

- a) Normal production condoms should be used, subject to any special packaging required to mask the product for the trial.
- b) The condom should be selected from a standard commercial design that is representative of condoms typically found in the market. Unusual designs should not be selected unless specifically justified by the trial design, in which case the scope of any claims supported by the trial can be subject to limitations.
- c) A standard type and quantity of lubricant should be used, preferably a 100 cSt to 350 cSt polydimethylsiloxane fluid. The quantity of lubricant should be 400 mg to 600 mg, as measured in ISO 4074:2015, Annex C. Equivalent lubricants based on aqueous and glycol formulations are acceptable provided they have no deleterious effect on the properties of the condoms. The selection of an unusual lubricant can result in any claims supported by the trial being subject to limitations.
- d) Selection of appropriate control condom should be justified with respect to study population of market and condom design and quality.

### **5.5.4 Expiration date of control condom**

Condoms should be selected from expiration date as specified in ISO 4074 or ISO 23409, from a single manufacturing lot (if possible) that is at least 2 years before expiration date at the commencement of the trial. Where possible, full manufacturing records should be available for the lot and the lot should be identified for full traceability. The lot should be thoroughly mixed and homogenized before the trial or any testing commences.

### **5.5.5 Storage conditions**

Condoms should be distributed and stored under such conditions that they are protected from prolonged exposure to temperatures in excess of 32 °C and any other environmental factors that could affect their quality. Storage conditions should be recorded and fully traceable.

### **5.5.6 Trial duration exceeds 1 year**

If the duration of the trial exceeds 1 year, the study sponsor should retain samples of both the test and control condoms (per initial sampling plan) and store them under the same conditions as the trial condoms. The retained samples should be retested at the end of the trial to confirm ongoing compliance with the airburst and freedom from holes requirements of ISO 4074 or ISO 23409, as appropriate, and characterize the properties of the condom. The results of any retests should be included in the trial report.

Manufacturers can retest the condoms at regular intervals (e.g. every 6 months) during the trial. If, at any stage, the retained samples fail to meet the airburst and freedom from holes requirements of ISO 4074 or ISO 23409, then consideration should be given to terminating the trial.

### **5.5.7 Sampling of control condoms for bench testing**

Sampling plans based on ISO 4074:2015, Annex B should be used to confirm compliance with the requirements of ISO 4074. Sampling plans based on ISO 23409:2011, Annex B should be used to confirm compliance with the requirements of ISO 23409.

## **5.6 Randomization**

Typically, the most efficient design for a condom functionality study, in terms of couple and condom numbers, is a randomized, crossover study. With the crossover study design, study subjects are first

given a set of one condom type to use and then return for a set of the other condom type. The protocol should contain a provision for the randomization scheme designating the sequence, e.g. test condoms first and control condoms second or the other way around.

### 5.7 Allocation concealment and study masking

To the degree possible, product assignment should be masked from study couples, investigators and data analysts after randomization. The study protocol should describe such masking procedures.

### 5.8 Use of additional lubricant

Lubricant is normally applied to the test and control condom before packaging. However, some test condoms can require users to apply lubricant. In addition, some users can desire additional lubricant.

The study protocol should address whether additional lubricants can be used with the condoms. The protocol should also specify the type and amount of lubricant available for the user. In addition, the case report forms should capture the use of any lubricants, including the type, amount (to the degrees possible) and location applied.

If the lubricant supplied to the study subjects is different from the lubricant applied prior to packaging, then material screening and testing should be conducted to ensure that any additional lubrication does not have any deleterious effects on either the test or control condoms.

**NOTE** It might be possible to adapt the testing principles of ASTM D7661 for testing the effects of lubricant on condom properties. ASTM D7661 is a test method to assess the compatibility of unlubricated natural rubber latex male condoms with lubricants.

### 5.9 Instructions and interactions with study couples

Detailed verbal and written instructions, as well as training, on correct condom use should be documented in the protocol and provided to all study participants.

The training and instructions should carefully address the following:

- a) purpose of study and duration of participation;
- b) clear definitions (with illustrations) of key outcome measures (clinical slippage, clinical breakage and safety);
- c) correct condom use;
- d) time frames for using test and control condoms and recording data;
- e) careful review of the “Individual Condom Use” case report form (CRF) and any other CRFs with instructions on how to properly complete them;
- f) telephone and/or other contact information for study coordinator.

In addition, couples should be instructed to contact research staff immediately if they encounter any problems related to the study. Serious adverse reactions should be reported immediately to the study sponsor and the ethics committee.

## 5.10 Interviews and data collection

### 5.10.1 Schedule for interviews and condom distribution

The protocol should have a schedule for CRF distribution.

- a) enrolment interview:
  - questionnaire, enrolment, provide condoms and condom use CRFs.

For crossover studies, only the first set of condoms should be distributed at the enrolment interview.
- b) mid-study interview, if crossover design:
  - collect individual condom use CRFs from first set and any unused condoms;
  - provide second set of condoms and individual condom use CRFs.
- c) exit interview:
  - collect individual condom use CRFs from the second set and any unused condoms.

For the purpose of this document, CRFs can be paper-based or electronic. Examples of CRFs are provided in the annexes.

### 5.10.2 Enrolment interview

The protocol should have provisions for an initial interview for obtaining informed consent from both partners, ensuring that inclusion/exclusion criteria are met and to provide study participants with instructions and initial set of condoms.

There should be an Enrolment CRF to collect the following data on the study participant:

- a) age, condom experience, reproductive history and other demographic information;
- b) risk of STI and pregnancy;
- c) method of contraception used during study;
- d) ability to comply with the study protocol (e.g. length of relationship, frequency of intercourse, problems with erection/ejaculation, use of genital jewellery, etc.);
- e) other, e.g. data on circumcision, genital mutilation (modification), as appropriate.

If desired, the protocol might contain provisions for a penis measurement kit. The kit should allow for a consistent means of measuring erect penis length and circumference. This information should be provided to the investigator at a later visit.

[Annex D](#) is a sample form for initial entry into the study (study entry CRF).

### 5.10.3 Individual condom use CRF

Per the randomization scheme, the protocol should contain a provision for providing the designated number of condoms (test or control) to the participating couples together with appropriate CRFs. The Condom Use CRF should provide for entries to collect the following event information for each condom.

Condom breakage and slippage studies are heavily reliant on user reports and memory recall. To minimize the impact of recall bias, a limited number of condoms (e.g. five) of each type should be used over no more than a 2-week to 3-week time period. Study instructions should direct participating

couples to complete the CRF for individual condom use as soon as possible after each sex act. The time frame should be no more than a few hours, not days, to reduce memory recall errors.

- a) package opened (yes/no);
- b) type of intercourse: vaginal, oral, anal;
- c) condom broken prior to intercourse while opening package or putting condom on;
- d) condom broken during intercourse;
- e) condom broken during withdrawal;
- f) location of break, if any;
- g) condom slipped completely off penis during intercourse;
- h) condom slipped completely off penis during withdrawal;
- i) semen leakage from condom, noticed by user;
- j) use of additional lubricant;
- k) safety-related events: burning, itching, irritation, etc.

The study sponsor can collect information on user acceptability.

Study couples should be instructed to examine the condom carefully after the penis is withdrawn but before the condom is removed from the penis. Breaks which are known to have occurred during removal of condom from penis should not be included in the calculation of clinical failure.

[Annex F](#) includes several CRFs from earlier studies that were used for recording the events of a single condom use. Study sponsors are encouraged to adopt one of these sample Condom Use CRFs for their own use.

#### **5.10.4 Mid-study CRF, crossover trial**

If a crossover trial is conducted, then the protocol should have a provision for a mid-study interview at which the initial set of individual condom use CRFs is collected from the participating couples and a second set of condoms and CRFs is given to the couple. A mid-study interview CRF could collect additional data on

- a) problems with condom use,
- b) acceptability,
- c) safety, and
- d) other.

[Annex E](#) is a sample mid-study CRF that might be adopted.

#### **5.10.5 Compiling data from CRFs**

The protocol should also explain how data will be collected from the Condom Use CRFs from each study arm and compiled on the following:

- a) number of packages opened;
- b) number of condoms used for vaginal intercourse;
- c) number of condoms broken prior to intercourse while opening package or putting condom on;

- d) number of condoms broken during intercourse or withdrawal (clinical breakage);
- e) number of condoms that slipped completely off penis during intercourse or withdrawal (clinical slippage);
- f) number of condoms used for oral sex or anal sex.

## **5.11 Data integrity**

### **5.11.1 General**

A condom breakage and slippage study is dependent upon user self-reports of clinical failures from each coital act. Considering the limits of human memory, the timeframe for recording these data by the user should be as immediate to each coital act as possible. Therefore, to ensure accuracy, reliability and traceability of all data, the study protocol should thoroughly address selection of study couples, instructions for study participants, timeframes for reporting events, design of coital diaries and other case report forms (CRFs), study schedules, as well as distribution of study condoms (test and control) and overall collection of study data.

### **5.11.2 Interactive voice response systems (IVRS)**

If using the telephone to collect daily coital information, sponsors are advised to implement interactive voice response systems (IVRS) that pose pre-recorded questions and enabling participants to respond using the keypad of their telephone. The advantage of this approach is that resources are “time stamped” and can potentially uncover participant fraud.

### **5.11.3 Mail-in and web-based data reporting**

Because a condom breakage and slippage study relies on patient-reported outcomes, it is possible to conduct such a study and allow study couples to submit their reports by mail or Internet.

This does not substitute for face-to-face interviews at study entry and completion. In this situation, procedures should be in place to minimize the potential for participant fraud.

The following are examples of procedures that should allow a third-party audit to validate the study and its underlying data.

- a) Clinical investigators should keep the envelopes when couples return information by mail. If no CRFs will be returned via mail, couples should be asked to send a personal identifier by mail (e.g. name of pet, oldest sibling, name of high school, etc.) which can be used to verify the participants' identity in future contacts. The investigator should keep the envelope and information in the letter for verification of enrolment.
- b) To verify the couple's participation, the informed consent document could request that, in addition to the collection of electronic data or data collected via the postal service, the clinical investigator might contact the study couple via telephone when either the sponsor monitors or the government agency conducts inspections of the clinical investigator's facility. Or, if the couple cannot be reached by telephone that day, a letter will be sent with a post card (pre-addressed to the investigator) that will verify the couple is a participant in the study. The telephone contact might ask for personal information that could verify the individual's participation. The post card should have the postal stamp and date of the couple's post office which could be compared with the couple's known address and the post card could require additional information that would help verify the couple's participation.

Study sponsors also need to be mindful of computerized systems used to create, modify, maintain, archive or transmit clinical data (e.g. e-Patient Reported Outcomes). The primary focus should be on computerized systems used at clinical sites to collect data in order to ensure the quality and integrity of electronic data, but same principles might be applied to computerized systems belonging to contract research organizations, data management centres and sponsors. Regulatory bodies that review such

studies and other persons using the data from computerized systems should have confidence that the data are no less reliable than data in paper form.

#### **5.11.4 Web-based data collection systems and additional suggestions**

Given the self-report nature of these condom studies, use of web-based data collection systems can be possible in certain regions with selected user populations. Conducting studies by web, email and postal communication can assist recruitment and facilitate the execution of the study. Loss to follow-up can be reduced since couples do not have to visit the study centre.

When conducting such studies, manufacturers and/or organizations responsible for the study should take steps to ensure the following:

- a) that full details of the proposed study are provided to potential couples to enable them to make an informed assessment of the risks prior to entering the study;
- b) that contact details are provided to allow potential couples to ask questions prior to entering the study;
- c) that written informed consent is obtained from both partners prior to enrolment and the provision of any samples;
- d) that adequate questions are asked to identify any participants that do not meet the inclusion criteria that should be excluded on the basis of one or more of the exclusion criteria or for whom the trial can pose a special risk;
- e) that adequate advice is provided to the couples about what actions to take if the condom should tear, break or slip off or if there is any adverse reaction to the condom. The couples should be provided with relevant contact details including telephone numbers and addresses to facilitate seeking advice from the study centre or other nominated sources of help and information;
- f) that adequate records are kept about the provision and return of samples and documentation including any questionnaires, record sheets, report forms, etc.

The manufacture or organizations concerned should take steps to verify that participants are genuine, meet the inclusion criteria and do not conflict with any of the exclusion criteria. Verification of addresses using appropriate databases and follow-up interviews, in person or by telephone, with a randomly selected proportion of the study population are ways of achieving this.

#### **5.12 Control of distribution chain**

The principles of ISO 13485 should be followed in the production of both test and control condoms. In general, all condoms used in a clinical trial, both test and control condoms, should have been produced, tested and foiled to production specifications for manufacturing, testing, lubrication and packaging. Documentation to this effect should be as complete as possible. At a minimum, each condom foil/individual container should be labelled with the batch number and the expiry date. The individual foil/container, the consumer package or both should protect the condoms from environmental damage as is appropriate for the product for at least the duration of the clinical trial period.

The manufacturer should take steps to ensure that the batch records are fully completed and approved by QC/QA prior to dispatch along with the necessary shipping documents to the clinical study centre. The manufacturer should also ensure that an adequate number of samples are retained for any follow-up investigations that can become necessary.

The clinical study centre should take steps to complete their receiving and inventory records and make checks on the sample packs to ensure they are free from any damage during transit.

The clinical study centre should store the samples according to the manufacturer's directions until they are ready to be given out to the study participants. The clinical study centre should follow the procedures for coding and any further labelling required as defined in the study protocol. The centre

should also ensure that, for traceability purposes, the individual foil/container with the manufacturer's batch number and expiry date remain visible to the user.

### 5.13 Analysis of returned condoms

It can be useful to analyse condoms that broke or slipped during the clinical trial. This kind of evaluation is a significant element in a general quality systems approach to device manufacture. It can also help explain some of the study findings when the trial is complete. [Annex H](#) contains a sample protocol for treating returned condoms. [Annex H](#) also includes diagrams illustrating a number of examples of condom break types.

**WARNING — The study described in [Annex H](#) requires direct contact with contaminated devices. It is strongly recommended that operators should wear gloves during the operation to reduce risks of any infectious accidents.**

### 5.14 Other methodological details

The study protocol can be needed to address the following concerns:

- a) language of instructions and case report forms and availability for review;
- b) regional differences in condom usage that could affect applicability of results to worldwide;
- c) social, cultural and economic setting of the study population, particularly literacy, access to medical care, community and family values, etc.;
- d) it is possible that naive condom users experience higher clinical failure rates until they become familiar with the products<sup>[8]</sup>; a brief, pre-planned condom use run-in period can be appropriate prior to enrolling study couples;
- e) if the study calls for run-in periods (learning period before use of test condom “counts” towards clinical failure rates) or wash-out periods (time period between use of test and control condoms), the protocol should provide the methodological details for these, including how such data will be managed;
- f) Monitoring Clinical Studies: Some regulatory bodies require clinical function studies for the approval of certain condoms. When this is the case, the study protocol or standard operating procedures should include a comprehensive monitoring plan
  - 1) to ensure the data are in compliance with Good Clinical Practice (GCP), Institutional Review Board (IRB) policies, as well as local regulatory regulations,
  - 2) to standardize the clinical data monitoring, and
  - 3) to ensure the validity, accuracy and integrity of the data.

A suitably qualified external trial monitor should be appointed to monitor the trial throughout its course from initiation to study close-out.

### 5.15 Statistical analysis plan

#### 5.15.1 General

The statistical analysis plan (SAP) should be developed and written with details on how the clinical study data will be analysed and interpreted. The SAP should be written and finalized prior to study implementation.

The following subclauses give examples of the components that should be considered when writing the SAP.

The design, analysis and interpretation of condom breakage and slippage studies should not be done without the help of an experienced statistician, familiar with non-inferiority testing and methods for making valid statistical inferences.

### 5.15.2 Primary study hypothesis

The primary end point in a clinical validation study of a new condom is total clinical failure. The primary research objective is to determine whether the expected total clinical failure rate of a new test condom is comparable with the expected total clinical failure rate of a legally marketed NRL male condom when used during vaginal intercourse. The clinical research question should be rephrased in statistical terms as a non-inferiority hypothesis. (For example, for synthetic condoms, the expected difference in total clinical failure rates, between the test and control condoms, is less than the amount,  $\delta$ , specified in ISO 23409.)

Therefore, the statistical plan should present a precise statement of the prospective study hypothesis in statistical terms, i.e. null ( $H_0$ ) and alternative ( $H_A$ ) hypotheses. For a condom non-inferiority study, this would typically look something like:

- $H_0$ : Expected test condom total clinical failure rate – expected control condom total clinical failure rate  $\geq \delta$ ;
- $H_A$ : Expected test condom total clinical failure rate – expected control condom total clinical failure rate  $< \delta$ .

If the null hypothesis of inferiority is rejected using an appropriate test statistic, then the alternate hypothesis of non-inferiority is accepted.

The failure rates observed in the clinical study based on a small number of condom uses per couple are only estimates of the expected rates that would be observed if an infinite number of condoms had been used. It is not sufficient for the observed difference in failure rates to be  $< \delta$  to conclude non-inferiority. Rather, the study results should provide a high degree of confidence that the difference in expected rates is  $< \delta$ .

### 5.15.3 Secondary study hypotheses

Based on the results from pilot studies and other factors (e.g. design or market feedback), it can be reasonable to test whether the new condom performs better than the control condom. As part of the SAP, study sponsors might prospectively specify a secondary hypothesis for superiority. If the study results support a conclusion of non-inferiority, then the secondary hypothesis might be tested.

Study sponsors should also develop secondary hypotheses to address the study end points of clinical slippage and breakage as individual variables, again comparing the test condom with the control condom. These should be done as non-inferiority analyses using a  $\delta$  for each individual variable that is a little smaller than that specified in the normative standard for total failure rate. For example, ISO 23409 specifies a  $\delta$  of 2,5 % for testing the total failure rates. Based on currently available data, it would be appropriate to use a  $\delta$  of 2,0 % to test breakage rates and slippage rates individually.

### 5.15.4 Study design

Typically, the most efficient study design for a condom functionality study is a two-period crossover trial.

The study should enrol a sufficient number of couples so a minimum of 200 couples complete the study. Because of attrition, it is prudent to enrol extra participants to ensure sufficient numbers at end of study. For example, if one expects a 15 % loss to follow-up, then the study should enrol at least 235 couples.

The study should ensure a minimum 1 000 uses of each condom type.

The study population and investigational sites should be heterogeneous and represent the target population. Therefore, the study should include multiple investigational sites and the number of study couples enrolled should be evenly distributed across sites.

Couples should be asked to use a specified number of condoms of each type during consecutive acts of vaginal intercourse in the first condom use period, followed by the same number of uses of the alternate condom type in a second and subsequent use period. Instances of condom use for anal intercourse should be excluded from the primary analysis. The number of each type of condom used (e.g. five if there are 200 participating couples) should be chosen to ensure that at least 1 000 uses of each condom type are available for the primary analysis.

Because some couples might not use their allocated number of condoms, it might be useful to provide all participating couples with extra condoms to help ensure the target number of 1 000 condom uses. Alternatively, the study design could specify a larger number of participating couples.

#### 5.15.5 Statistical analysis

It is recommended that the statistical analysis plan be specified prior to implementation of the study. This includes plans for primary analyses, as well as all key subgroup and secondary analyses.

Primary analyses should be performed using all available condom use data. Data from all study sites should be pooled unless statistically significant and clinically meaningful interactions between centre and condom type are detected. If such interactions are observed, comparisons should be made separately for each centre. Any missing data (e.g. due to non-use or data errors) should be ignored in the primary analyses unless patterns are identified which suggest condom type comparisons can be biased. If such patterns are observed, efforts should be made to identify their causes and effects on analyses.

Analyses should be based on a confidence interval approach to non-inferiority testing<sup>[3]</sup> based on the null and alternative hypotheses specified in [5.15.2](#).

The outcomes of each condom use by a particular couple are expected to be more alike than the outcomes of condom use by another couple. This will result in correlated data that should be accounted for in the statistical analysis. One approach would be to use generalized estimating equations (GEE) with an identity link function and an independent working correlation structure<sup>[5]</sup>. This method is described in further detail for condom studies in Reference [\[8\]](#).

The proportion of test and control condoms experiencing clinical failure will be calculated. The difference in proportions, and an upper one-sided 95 % confidence limit for the difference, will be reported. An upper limit that is less than  $\delta$  will be interpreted as statistical evidence that the test condom is non-inferior to the control condom with respect to clinical failure.

An upper one-sided 97,5 % confidence limit for the difference that is less than 0 % could be further interpreted as statistical evidence that the test condom is superior to the control condom.

Study power is the probability of concluding non-inferiority. In addition to the number of enrolled couples and condom uses, the power of the study will depend on the degree of correlation and the true clinical breakage and slippage rates. Although these quantities are unknown, sample size calculations can typically be made assuming a correlation of no more than 0,2. Also, to be conservative, one should assume failure rates corresponding to the upper range of expected rates in the target population (e.g. 3 %). This need for an estimate of expected failure rates underscores the importance of pilot studies.

NOTE [Annex A](#) provides an example formula for the power calculation.

#### 5.15.6 Additional statistical comments and concerns

Low total clinical failure proportions (<0,5 %) in the control arm can make implementing a functionality study challenging; careful choice of the study population to minimize this possibility is essential.

Strongly consider a pilot study if there is no objective data on the anticipated clinical failure rates of the test condom in the study population.

## **5.16 Clinical study results: Review and interpretation**

### **5.16.1 General**

When the clinical validation study and statistical analysis are completed, it is important to critically evaluate the results to determine whether the test condom performs acceptably well in comparison with the control condom. Principles for such an evaluation include careful consideration of the control condom characteristics, characteristics of the couples participating in the study, reliability of self-reporting and the rates for slippage and breakage.

### **5.16.2 Total clinical failure rates for control condom**

The total clinical failure rates during actual use should be in the range of 0,5 % to 4,0 % for condoms made from natural rubber latex. If the total clinical failure rates for the control condom fall outside of this range, then a rationale should be provided to justify the validity of the trial. One should carefully investigate the design and conduct of the study to determine if there are any unusual factors that could have contributed to the unusually high or low rates (e.g. study population factors, study bias, breaches in data integrity, participant fraud, etc.).

### **5.16.3 Non-inferiority**

The primary hypothesis for the clinical validation study is that the performance of the test condom is not inferior to that of a selected control condom with respect to total clinical failure.

The study should be sufficiently documented to allow an evaluator to independently reproduce the statistical results.

If the upper one-sided 95 % confidence limit for the difference in the total clinical failure rates (test minus control) is less than  $\delta$ , then this can be interpreted as statistical evidence that the test condom is non-inferior to the standard control condom. One can then conclude that the test condom is comparable in performance with the control condom used in the study.

If the upper bound on the confidence interval around the difference in rates exceeds  $\delta$ , then the evaluator should systematically explore the underlying reasons. One reason can be that the test condom is inferior to the control condom. However, other factors, including the user population and methodological problems, might explain such study findings.

### **5.16.4 Superiority**

If the upper one-sided 97,5 % confidence limit of the difference in total clinical failure rates is less than 0 %, this might be interpreted as statistical evidence that the test condom is superior to the NRL control condom with respect to total clinical failure.

### **5.16.5 Safety (adverse events)**

Any reports of adverse events or complaints should be thoroughly investigated to determine whether the test condom poses an unacceptable safety risk in comparison with the control condom. Individual complaints of irritation, burning, itching, bleeding, etc., should be followed up with clinical evaluation. The study report should fully address these events. For each event, provide information on severity, duration and relatedness and how each event was clinically resolved.

#### **5.16.6 What happens if one is unable to conclude non-inferiority?**

If the study data do not allow one to conclude that the total clinical failure rate of the test condom is less than  $\delta$  higher than the corresponding control condom rate, then one cannot make a statistical conclusion of non-inferiority.

Upon request, an evaluator could critically review the study design and data to determine whether the test condom might still be considered suitable for marketing. Under this circumstance (no statistically-based conclusion of non-inferiority), a regulatory body can consider other factors, such as:

- a) the individual clinical slippage and breakage rate differences between condom types;

NOTE Under these circumstances, there can be a role for a follow-up study and/or a meta-analysis of this and previous studies.

- b) beneficial qualities of the test condom that can increase condom use;
- c) labelling mitigation (e.g. to be used only by persons who are latex sensitive, place test results in labelling, etc.).

## Annex A (informative)

### Formula for power calculation

Denote the true (unknown) test and control condom failure probabilities as  $F_T$  and  $F_C$ , respectively, and let  $\Delta = F_T - F_C$ . Also, define the correlation between condom uses by  $\rho$  and assume that each couple uses  $Z$  condoms of each type. Then the number of couples required to have  $P \times 100$  % power (e.g.  $P = 0,9$  corresponds to 90 % power) to conclude non-inferiority is given by [Formula \(A.1\)](#):

$$N = \{G(P) + 1,645\}^2 \times \text{Var}(\Delta) / \{(\delta - \Delta)^2\} \quad (\text{A.1})$$

where

$$\text{Var}(\Delta) = F_T(1 - F_T) \times \{1 + (Z - 1)\rho\}/Z + F_C(1 - F_C) \times \{1 + (Z - 1)\rho\}/Z - 2\rho \times \{F_T(1 - F_T) \times F_C(1 - F_C)\}^{1/2}$$

is a measure of the variance of the difference in failure rates and where  $G(\cdot)$  is the inverse cumulative normal probability function.

For example, if  $F_T = F_C = 0,03$ ,  $\rho = 0,2$  and each couple uses  $Z = 5$  condoms per type, then  $\text{Var}(\Delta) = 0,009\ 3$ . In order to have 90 % power,  $G(0,9) = 1,282$  and  $N = 128$  couples should be enrolled for  $\delta = 0,025$ .

If one does not perform a crossover trial, then [Formula \(A.1\)](#) provides the number of couples that should use each type (i.e. there should be  $2N$  total enrolled couples) where  $\text{Var}(\Delta) = F_T(1 - F_T) \times \{1 + (Z - 1)\rho\}/Z + F_C(1 - F_C) \times \{1 + (Z - 1)\rho\}/Z$ .

For the above example (alternate to the crossover design),  $N = 287$  couples using five condoms of one type plus 287 different couples using five condoms of the other type to achieve 90 % power, i.e. 574 total couples, 287 in each arm.

## **Annex B** (informative)

### **Pilot clinical investigation (sample outline)**

#### **B.1 General**

The following is an outline for conducting a clinical feasibility study of a new condom to obtain a preliminary estimate of slippage and breakage during use. As with the pivotal breakage and slippage study, such feasibility studies should also comply with ISO 14155.

#### **B.2 Study design**

- $n = 35$  couples, typically need to recruit 40 to 45 couples to finish with 35.
- Each couple to use three condoms of the test product and natural rubber latex control.
- Double-masked randomized crossover design.
- Each couple should be given two consecutive weeks to complete each evaluation (one type of condom).
- Each couple should complete a diary of each coital event when one of the samples is used, including the sexual position used.
- At the end of the use of each product, the couple should be interviewed either by telephone, Internet or by clinic visit, the latter being preferred.
- Clinical end points should be condom slippage and breakage during use, as well as any genito-urinary adverse events.
- Socio-economic data should be collected and recorded (e.g. age, race, level of education).
- Financial payment to panellists should be made at the end of the study.

#### **B.3 Inclusion criteria**

- Couples not at risk of pregnancy (using alternate contraception).
- No known sexually transmitted infections, including HIV/AIDS.
- Couples should be experienced condom users, minimum 10 male condoms used in the last 12 months.
- Subjects between 18 to 45 years of age.
- Monogamous heterosexual couples who agree to practice vaginal sex only during the study.

#### **B.4 Exclusion criteria**

- Couples who work for the clinical testing laboratory or who are relatives of staff of the clinical test laboratory or a sponsor of the study.
- Participants with known allergy to natural rubber latex or material(s) of test condom.

- Participants with known sensitivity to the residual chemicals used in the manufacture of natural rubber latex condoms or the test condom materials.
- Couples where one knowingly has a sexually transmitted infection.

### **B.5 Informed consent**

Participating study subjects should be given appropriate informed consent. See [5.4](#).

### **B.6 Adverse event report form**

A draft template is attached (see [Annex G](#)).

### **B.7 Statistical analysis**

- To be determined, 95 % confidence interval.
- Confounding factors to be noted are couples who cluster break on either the test or control product and if more than 20 % of the recruited fail to complete the study.



## Annex D

(informative)

## CRF — Study entry (sample)

## CALIFORNIA FAMILY HEALTH COUNCIL - INITIAL HISTORY

ID <span style="border: 1px solid black; display: inline-block; width: 20px; height: 15px;"></span> <span style="border: 1px solid black; display: inline-block; width: 20px; height: 15px;"></span> <span style="border: 1px solid black; display: inline-block; width: 20px; height: 15px;"></span> <span style="border: 1px solid black; display: inline-block; width: 20px; height: 15px;"></span> - <span style="border: 1px solid black; display: inline-block; width: 20px; height: 15px;"></span>		Date <span style="border: 1px solid black; display: inline-block; width: 20px; height: 15px;"></span> <span style="border: 1px solid black; display: inline-block; width: 20px; height: 15px;"></span> <span style="border: 1px solid black; display: inline-block; width: 20px; height: 15px;"></span> <span style="border: 1px solid black; display: inline-block; width: 20px; height: 15px;"></span>																															
<p><b>1. What is your birthdate (month/day/year) ?</b></p> <div style="display: flex; justify-content: space-around; align-items: center;"> <span style="border: 1px solid black; width: 20px; height: 20px;"></span> <span style="border: 1px solid black; width: 20px; height: 20px;"></span> <span style="border: 1px solid black; width: 20px; height: 20px;"></span> <span style="border: 1px solid black; width: 20px; height: 20px;"></span> <span style="border: 1px solid black; width: 20px; height: 20px;"></span> </div>																																	
<p><b>2. What is the highest level of education you have completed?</b></p> <div style="display: flex; flex-direction: column;"> <div><input type="checkbox"/> 1 8th grade or less</div> <div><input type="checkbox"/> 2 Some high school</div> <div><input type="checkbox"/> 3 High school diploma or equivalent (GED)</div> <div><input type="checkbox"/> 4 Some college</div> <div><input type="checkbox"/> 5 BA (Bachelor's degree)</div> <div><input type="checkbox"/> 6 Post-graduate degree</div> </div>																																	
<p><b>3. What is your race/ethnicity?</b></p> <div style="display: flex; flex-direction: column;"> <div><input type="checkbox"/> 1 White</div> <div><input type="checkbox"/> 2 Hispanic/Latino</div> <div><input type="checkbox"/> 3 African American</div> <div><input type="checkbox"/> 4 Asian or Pacific Islander</div> <div><input type="checkbox"/> 5 Native American</div> <div><input type="checkbox"/> 6 More than one, Describe: _____</div> </div>																																	
<p><b>4. Including your study partner, how many sexual partners have you had in the last 6 months?</b> _____</p>																																	
<p><b>5. Are you allergic to latex or polyurethane?</b></p> <div style="display: flex; flex-direction: column;"> <div><input type="checkbox"/> 0 No</div> <div><input type="checkbox"/> 1 Yes</div> </div>																																	
<p><b>6. In the last year have you used injection drug needles?</b></p> <div style="display: flex; flex-direction: column;"> <div><input type="checkbox"/> 0 No</div> <div><input type="checkbox"/> 1 Yes</div> </div>																																	
<p><b>7. In your lifetime, how many times have you had each of the following?</b></p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th></th> <th style="text-align: center;">Never</th> <th style="text-align: center;">1-2x</th> <th style="text-align: center;">3+x</th> <th></th> </tr> </thead> <tbody> <tr> <td>Trichomonas .....</td> <td style="text-align: center;"><input type="checkbox"/> 0</td> <td style="text-align: center;"><input type="checkbox"/> 1</td> <td style="text-align: center;"><input type="checkbox"/> 2</td> <td>→</td> </tr> <tr> <td>Chlamydia .....</td> <td style="text-align: center;"><input type="checkbox"/> 0</td> <td style="text-align: center;"><input type="checkbox"/> 1</td> <td style="text-align: center;"><input type="checkbox"/> 2</td> <td>→</td> </tr> <tr> <td>Gonorrhea .....</td> <td style="text-align: center;"><input type="checkbox"/> 0</td> <td style="text-align: center;"><input type="checkbox"/> 1</td> <td style="text-align: center;"><input type="checkbox"/> 2</td> <td>→</td> </tr> <tr> <td>Syphilis .....</td> <td style="text-align: center;"><input type="checkbox"/> 0</td> <td style="text-align: center;"><input type="checkbox"/> 1</td> <td style="text-align: center;"><input type="checkbox"/> 2</td> <td>→</td> </tr> <tr> <td>Genital herpes .....</td> <td style="text-align: center;"><input type="checkbox"/> 0</td> <td style="text-align: center;"><input type="checkbox"/> 1</td> <td style="text-align: center;"><input type="checkbox"/> 2</td> <td>→</td> </tr> </tbody> </table>					Never	1-2x	3+x		Trichomonas .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	→	Chlamydia .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	→	Gonorrhea .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	→	Syphilis .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	→	Genital herpes .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	→
	Never	1-2x	3+x																														
Trichomonas .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	→																													
Chlamydia .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	→																													
Gonorrhea .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	→																													
Syphilis .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	→																													
Genital herpes .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	→																													
<p><b>8. Have you ever been diagnosed with any of the following?</b></p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th></th> <th style="text-align: center;">Never</th> <th style="text-align: center;">Yes</th> <th></th> </tr> </thead> <tbody> <tr> <td>HIV .....</td> <td style="text-align: center;"><input type="checkbox"/> 0</td> <td style="text-align: center;"><input type="checkbox"/> 1</td> <td rowspan="3">→ If yes, What type? _____</td> </tr> <tr> <td>Hepatitis .....</td> <td style="text-align: center;"><input type="checkbox"/> 0</td> <td style="text-align: center;"><input type="checkbox"/> 1</td> </tr> <tr> <td>HPV/Genital warts (condylomata) .....</td> <td style="text-align: center;"><input type="checkbox"/> 0</td> <td style="text-align: center;"><input type="checkbox"/> 1</td> </tr> </tbody> </table>					Never	Yes		HIV .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1	→ If yes, What type? _____	Hepatitis .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1	HPV/Genital warts (condylomata) .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1																
	Never	Yes																															
HIV .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1	→ If yes, What type? _____																														
Hepatitis .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1																															
HPV/Genital warts (condylomata) .....	<input type="checkbox"/> 0	<input type="checkbox"/> 1																															
<p style="text-align: center;"><b>IF &gt; 0:</b></p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2" style="text-align: left; padding: 5px;">What is the date of most recent infection/outbreak?</th> <th colspan="2" style="text-align: left; padding: 5px;">Were you treated for the infection/outbreak?</th> </tr> <tr> <th style="text-align: center; padding: 5px;">Month</th> <th style="text-align: center; padding: 5px;">Year</th> <th style="text-align: center; padding: 5px;">Yes</th> <th style="text-align: center; padding: 5px;">No</th> </tr> </thead> <tbody> <tr> <td style="padding: 5px;">If yes: _____</td> <td style="padding: 5px;">_____</td> <td style="padding: 5px;">→ _____</td> <td style="padding: 5px;">_____</td> </tr> <tr> <td style="padding: 5px;">If yes: _____</td> <td style="padding: 5px;">_____</td> <td style="padding: 5px;">→ _____</td> <td style="padding: 5px;">_____</td> </tr> <tr> <td style="padding: 5px;">If yes: _____</td> <td style="padding: 5px;">_____</td> <td style="padding: 5px;">→ _____</td> <td style="padding: 5px;">_____</td> </tr> <tr> <td style="padding: 5px;">If yes: _____</td> <td style="padding: 5px;">_____</td> <td style="padding: 5px;">→ _____</td> <td style="padding: 5px;">_____</td> </tr> </tbody> </table>				What is the date of most recent infection/outbreak?		Were you treated for the infection/outbreak?		Month	Year	Yes	No	If yes: _____	_____	→ _____	_____	If yes: _____	_____	→ _____	_____	If yes: _____	_____	→ _____	_____	If yes: _____	_____	→ _____	_____						
What is the date of most recent infection/outbreak?		Were you treated for the infection/outbreak?																															
Month	Year	Yes	No																														
If yes: _____	_____	→ _____	_____																														
If yes: _____	_____	→ _____	_____																														
If yes: _____	_____	→ _____	_____																														
If yes: _____	_____	→ _____	_____																														
<p><b>9. On average, how often do you and your current partner have vaginal intercourse?</b></p> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <div><input type="checkbox"/> 1 Less than 4 times per month</div> <div><input type="checkbox"/> 2 4 - 6 times per month</div> </div> <div style="width: 45%;"> <div><input type="checkbox"/> 3 7 - 10 times per month</div> <div><input type="checkbox"/> 4 More than 10 times per month</div> </div> </div>																																	
<p><b>10. In the last year have you had sex with a man?</b></p> <div style="display: flex; flex-direction: column;"> <div><input type="checkbox"/> 0 No</div> <div><input type="checkbox"/> 1 Yes</div> </div>																																	
<p style="text-align: center;"><b>FEMALE ONLY:</b></p> <p><b>11. How would you describe your living arrangement?</b></p> <div style="display: flex; flex-direction: column;"> <div><input type="checkbox"/> 1 Married to study partner</div> <div><input type="checkbox"/> 2 Not married to but living with study partner</div> <div><input type="checkbox"/> 3 Not married to or living with study partner</div> </div>																																	
<p><b>12. When did you begin a sexual relationship with your current partner? (Month/Year)</b> _____ / _____</p>																																	
<p><b>13. What is your current method of birth control?</b></p> <div style="display: flex; flex-direction: column;"> <div><input type="checkbox"/> 1 Birth control pills</div> <div><input type="checkbox"/> 2 Depo Provera shot</div> <div><input type="checkbox"/> 3 Contraceptive patch</div> <div><input type="checkbox"/> 4 IUD</div> <div><input type="checkbox"/> 5 Sterilization (tubal ligation or vasectomy)</div> <div><input type="checkbox"/> 6 Other, Describe: _____</div> </div>																																	

RA Init-#:        -        Date:        /        /        Edited by:        Date:        /        /        Batch-Record #:        -

INITIAL HISTORY

ID       -

Date

<div>1. What is your birthdate (month/day/year) ? <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/></div> <div>2. What is your employment status? (Check one only.) 1 <input type="checkbox"/> Full-time 2 <input type="checkbox"/> Part-time 3 <input type="checkbox"/> Student 4 <input type="checkbox"/> Unemployed 5 <input type="checkbox"/> Homemaker 6 <input type="checkbox"/> Disabled</div> <div>3. What is the highest level of education you have completed? 1 <input type="checkbox"/> 8th grade or less 2 <input type="checkbox"/> Some high school 3 <input type="checkbox"/> High school diploma or equivalent (GED) 4 <input type="checkbox"/> Some college 5 <input type="checkbox"/> BA (Bachelor's degree) 6 <input type="checkbox"/> Post-graduate degree</div> <div>4. What is your race/ethnicity? 1 <input type="checkbox"/> White 2 <input type="checkbox"/> Hispanic/Latino 3 <input type="checkbox"/> African American 4 <input type="checkbox"/> Asian or Pacific Islander 5 <input type="checkbox"/> Native American 6 <input type="checkbox"/> More than one Please describe : <input type="text"/></div> <div>5. What is your total combined household annual income? 1 <input type="checkbox"/> \$0 - 5,000 2 <input type="checkbox"/> \$5,001 - 10,000 3 <input type="checkbox"/> \$10,001 - 20,000 4 <input type="checkbox"/> \$20,001 - 30,000 5 <input type="checkbox"/> \$30,001 - 40,000 6 <input type="checkbox"/> \$40,001 - 50,000 7 <input type="checkbox"/> \$50,001 - 60,000 8 <input type="checkbox"/> More than \$60,000</div> <div>6. Do you smoke? (cigarettes, pipes, cigars) 0 <input type="checkbox"/> No, Never 1 <input type="checkbox"/> No, I quit 2 <input type="checkbox"/> Yes</div> <div>7. How often do you drink alcoholic beverages? 0 <input type="checkbox"/> Never 1 <input type="checkbox"/> Less than monthly 2 <input type="checkbox"/> Monthly <input type="text"/> Number of drinks/beers per month 3 <input type="checkbox"/> Weekly <input type="text"/> Number of drinks/beers per week 4 <input type="checkbox"/> Daily <input type="text"/> Number of drinks/beers per day</div> <div>8. How many sexual partners have you had during your lifetime? <input type="text"/></div> <div>9. Including your study partner, how many sexual partners have you had in the last 6 months? <input type="text"/></div>	<div>10. How many times have you been pregnant (female) or responsible for a pregnancy (male) ? <input type="text"/></div> <div>11. How many times have you used male condoms with <u>all</u> partners, including your current partner? 0 <input type="checkbox"/> Never <input type="text"/> If Never, skip to Q15 1 <input type="checkbox"/> 1 - 2 times 2 <input type="checkbox"/> 3 - 10 times 3 <input type="checkbox"/> 11 - 50 times 4 <input type="checkbox"/> 51 or more times</div> <div>12. When did you last use a male condom with <u>any</u> partner, including your current partner? 1 <input type="checkbox"/> Less than 6 months ago 2 <input type="checkbox"/> Between 6 months and 1 year ago 3 <input type="checkbox"/> Between 1 and 5 years ago 4 <input type="checkbox"/> More than 5 years ago</div> <div>13. How many times have you experienced a male condom break during vaginal intercourse with <u>other</u> partners (not including your current partner)? N <input type="checkbox"/> Not applicable (no other partners/ no condom use w/other partners) 0 <input type="checkbox"/> 0 (Never) 1 <input type="checkbox"/> 1 - 2 times 2 <input type="checkbox"/> 3 - 5 times 3 <input type="checkbox"/> 6 - 10 times 4 <input type="checkbox"/> More than 10 times</div> <div>14. Have you <u>ever</u> used a polyurethane (non-latex) condom? 0 <input type="checkbox"/> No <input type="text"/> If No, skip to Q#15 1 <input type="checkbox"/> Yes 2 <input type="checkbox"/> Unsure <input type="text"/> If Unsure, skip to Q#15 <div>14a. If Yes, what was your impression of the condom? 0 <input type="checkbox"/> Negative 1 <input type="checkbox"/> Positive 2 <input type="checkbox"/> Neutral</div></div> <div>15. Are you allergic to latex or polyurethane, or have you had problems when you used latex or polyurethane products? 0 <input type="checkbox"/> No 1 <input type="checkbox"/> Yes, Describe: <input type="text"/></div> <div>16. Do you have any genital piercings? 0 <input type="checkbox"/> No 1 <input type="checkbox"/> Yes, Describe: <input type="text"/></div> <div>17. Are you currently participating in any other clinical studies? 0 <input type="checkbox"/> No 1 <input type="checkbox"/> Yes, Describe: <input type="text"/></div>
---	--

ID  -

**MALE ONLY:**

**23. On average, how often do you and your current partner have vaginal intercourse?**

- 1 ☐ Less than 4 times per month    3 ☐ 7 - 10 times per month  
2 ☐ 4 - 6 times per month    4 ☐ More than 10 times per month

**24. How many times have you used a male condom with your current partner?**

- 0 ☐ 0 (Never)  $\implies$  If Never, skip to Q#25  
1 ☐ 1 - 2 times  
2 ☐ 3 - 10 times  
3 ☐ 11 - 50 times  
4 ☐ More than 50 times

**24a. How many times have you experienced a male condom break during vaginal intercourse with your current partner?**

- 0 ☐ 0 (Never)    3 ☐ 6 - 10 times  
1 ☐ 1 - 2 times    4 ☐ More than 10 times  
2 ☐ 3 - 5 times

**25. Are you circumcised (see diagram) ?**    0 ☐ No    1 ☐ Yes



**26. In your lifetime, how many times have you had each of the following?**

- Difficulty getting an erection:    If Rarely or Sometimes:  
0 ☐ Never    1 ☐ Rarely    2 ☐ Sometimes    # Times in last month: \_\_\_\_\_  
Difficulty maintaining an erection:  
0 ☐ Never    1 ☐ Rarely    2 ☐ Sometimes    # Times in last month: \_\_\_\_\_  
Difficulty achieving ejaculation:  
0 ☐ Never    1 ☐ Rarely    2 ☐ Sometimes    # Times in last month: \_\_\_\_\_

**27. Have you ever been diagnosed with any of the following?**

- |   | Never                      | Yes                        |
|---|----------------------------|----------------------------|
| Undescended testes . . . . .                | 0 <input type="checkbox"/> | 1 <input type="checkbox"/> |
| Urethra opening on underside of penis . . . | 0 <input type="checkbox"/> | 1 <input type="checkbox"/> |

**28. In the last year have you had sex with a man?**

- 0 ☐ No  
1 ☐ Yes

**FEMALE ONLY:**

**29. How would you describe your living arrangement?**

- 1 ☐ Married to study partner  
2 ☐ Not married to but living with study partner  
3 ☐ Not married to or living with study partner

**30. How long have you been with your current partner?**

- ☐ Less than one year: \_\_\_\_\_ months  
☐ More than one year: \_\_\_\_\_ years

**31. What is your current method of birth control?**

- 1 ☐ Birth control pills    4 ☐ IUD  
2 ☐ Depo Provera shot    5 ☐ Sterilization (tubal ligation/vasectomy)  
3 ☐ Contraceptive patch    6 ☐ I'm pregnant  
6 ☐ Other, Describe: \_\_\_\_\_

**32. How often do you and your partner use additional lubricants during vaginal intercourse?**

- 0 ☐ Never  
1 ☐ Rarely  
2 ☐ Sometimes  
3 ☐ Often
- If yes, what lubricants do you use? \_\_\_\_\_

**33. In your lifetime, how many times have you had each of the following?**

- |                                   | Never                      | 1-2x                       | 3+x                        |
|-----------------------------------|----------------------------|----------------------------|----------------------------|
| Yeast infection . . . . .         | 0 <input type="checkbox"/> | 1 <input type="checkbox"/> | 2 <input type="checkbox"/> |
| Other vaginal infection . . . . . | 0 <input type="checkbox"/> | 1 <input type="checkbox"/> | 2 <input type="checkbox"/> |
- If yes to Other infection, Describe: \_\_\_\_\_

RA Init-#: \_\_\_\_\_ - \_\_\_\_\_ Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ Edited by: \_\_\_\_\_ Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ Batch-Record #: \_\_\_\_\_ - \_\_\_\_\_

NOTE CFHC granted permission for its CRFs to be used in condom function studies.

Annex E  
(informative)

CRF — Mid-study (sample)

ACCEPTABILITY SURVEY

MALE    FEMALE

-

IDBirthdateDate Form Completed

Visit Type (circle):    2    3

COMPLETE THIS FORM SEPARATELY FROM YOUR PARTNER. PLEASE RECORD YOUR HONEST OPINIONS.

1. Using the 1 to 7 scale, please circle the number that best describes your experience with the study condom you just used:

	Strongly Disagree					Strongly Agree	
a. The study condom was easy to put on.	1	2	3	4	5	6	7
b. The study condom had a pleasant smell or no smell.	1	2	3	4	5	6	7
c. The study condom made little or no noise.	1	2	3	4	5	6	7
d. The study condom felt soft.	1	2	3	4	5	6	7
e. The study condom was comfortable.	1	2	3	4	5	6	7
f. The study condom increased sensitivity and stimulation.	1	2	3	4	5	6	7
g. The study condom transmitted body heat.	1	2	3	4	5	6	7
h. I liked the amount of lubricant on the outside of the study condom.	1	2	3	4	5	6	7
i. I liked the amount of lubricant on the inside of the study condom.	1	2	3	4	5	6	7
j. I liked the way the lubricant felt.	1	2	3	4	5	6	7
k. The lubricant on the study condom lasted long enough.	1	2	3	4	5	6	7
l. The study condom was not messy.	1	2	3	4	5	6	7
m. My overall sexual experience was good while using the study condom.	1	2	3	4	5	6	7
n. I liked the study condom as much as other condoms I have used.	1	2	3	4	5	6	7
o. MALES ONLY: The study condom fit well.	1	2	3	4	5	6	7

2. Would you purchase a condom like the study condom you just used?

0

No: skip to Q4

1

Maybe

2

Yes

3. Would you be willing to pay more for this condom than condoms you've used in the past? Based on a box of 6 condoms, how much more would you pay?

0

No more

1

Up to 50¢ more

2

Up to \$1.00 more

3

Up to \$2.00 more

4. What was the ONE thing you liked best about the study condom?

5. What was the ONE thing you liked least about the study condom?

6. How highly would you recommend the study condom you just used?

1

Highly recommend

2

Recommend

3

Recommend with reservations

4

Not recommend

RA Init-#:

-

Date:

/

/

Edited by:

Date:

/

/

Batch-Record #:

-

NOTE      CFHC granted permission for its CRFs to be used in condom function studies.

24

© ISO 2017 – All rights reserved

## **Annex F** (informative)

### **CRF — Individual condom use (sample)**

The following are three separate paper-based examples of CRFs used to capture the key event information after condom use, i.e. slippage events and breakage events. It is critical that study participants enter this information into the CRF as soon after each coital act as practicable. They should not wait several days or a week and then try to recall events from multiple coital acts over that period.

It is not unusual for study sponsors to attempt to collect additional use information from the study participants. Keep in mind that the CRF for an individual condom use should be clear and easy to follow. Any attempt to collect non-primary outcome data should be weighed against the potential for making the CRF more confusing.

California Family Health Council (CFHC), Family Health International (FHI) and Sagami-France provided the three CRF examples and all three granted permissions for these CRFs to be reproduced or adapted by any interested study sponsor.

EXAMPLE 1 Two-page CRF for individual condom use, submitted by the CFHC.

This CRF is intended to be used as a two-sided form that fits on a single piece of paper. Questions in red are of primary interest.

CA FAMILY HEALTH COUNCIL - CONDOM REPORT

Male Birthdate

Condom #

Couple ID#

Date Condom Used

1. Did the following happen with this condom use?

(Check Agree or Disagree for each statement.)

Agree

Disagree

Male did not drink alcohol in the 2 hours before intercourse

Female did not drink alcohol in the 2 hours before intercourse

Condom was stored in a cool dry place

We opened the package without using any sharp objects

We used a new condom that had not been used before

We did not use any oil-based lubricants

The female had not used a vaginal product like Miconazole in the past 3 days

The female was not on her period

The penis was erect when we put on the condom

We pushed out all the air from the tip of the condom before we put it on

We unrolled the condom on the penis

2. What happened with this condom? (Check only one.)

☐ Did not use for intercourse - Condom tore when opening package

☐ Did not use for intercourse - Condom was defective

☐ Did not use for intercourse - Condom tore when putting on

☐ Did not use for intercourse - Could not unroll condom when putting on

☐ Did not use for intercourse - Other reason

☐ Used for intercourse - Condom was NOT on when intercourse stopped, describe

☐ Used for intercourse - Condom WAS on when intercourse stopped

☐ Other, describe

3. Who put on this condom?

☐ Did not try to put condom on

☐ Man

☐ Both partners together

☐ Woman

4. Did you have any problems putting on this condom?

(Check only 1 answer.)

☐ Did not try to put condom on

☐ No

☐ Yes - Started to put condom on backwards/inside out

☐ Yes - Trouble unrolling

☐ Yes - Fit too tight

☐ Yes - Other, describe

5. After you unrolled the condom, did it cover the entire shaft of the penis?

☐ Did not unroll the condom

☐ Yes

☐ No

6. Did you add lubrication before starting intercourse?

☐ No

☐ Yes, Astroglide

☐ Yes, other

If This Condom NOT Used for Intercourse, Skip to Q#17

7. Did you add lubrication after starting intercourse?

☐ No

☐ Yes, Astroglide

☐ Yes, other

8. Which of the following sexual positions did you use with this condom? (Check all that apply.)

☐ Man on top

☐ Side by side

☐ Woman on top

☐ Rear entry (vaginal)

9. Did this condom break or tear?

☐ No - Skip to Q#10

☐ Yes

9a. Where did this condom break or tear?

☐ At the tip of the condom (closed end)

☐ At the middle of the condom

☐ At the open end (rim) of the condom

☐ At more than one location

☐ Other, describe

☐ Don't know where

9b. What position were you using when this condom broke?

☐ Man on top

☐ Rear entry (vaginal)

☐ Don't know

☐ Woman on top

☐ Side by side

☐ Not applicable

9c. When do you think this condom break occurred?

☐ During vaginal intercourse & before ejaculation

☐ During ejaculation

☐ After ejaculation & before withdrawal

☐ During withdrawal

☐ While taking off the condom

☐ Other, describe

☐ Don't know when

10. Did this condom slip completely off the penis? (Check one.)

☐ No

☐ Yes, During vaginal intercourse & before ejaculation

☐ Yes, During ejaculation

☐ Yes, After ejaculation & before withdrawal

☐ Yes, During withdrawal

☐ Yes, Couldn't tell when

CFHC 4918-24-08

26

© ISO 2017 – All rights reserved

<b>11. Did you experience any of the following while using this condom?</b> (Check Yes or No for every item.)		No	Yes		
We started intercourse without the condom .....		<input type="checkbox"/>	<input type="checkbox"/>		
The condom slipped <u>along the shaft</u> of the penis <u>during</u> intercourse (see Diagram D) .....		<input type="checkbox"/>	<input type="checkbox"/>		
The condom bunched up during intercourse (see Diagram C) .....		<input type="checkbox"/>	<input type="checkbox"/>		
The condom stretched out of shape (see Diagram D) .....		<input type="checkbox"/>	<input type="checkbox"/>		
The condom fit was too tight .....		<input type="checkbox"/>	<input type="checkbox"/>		
Not enough lubrication/too dry during intercourse .....		<input type="checkbox"/>	<input type="checkbox"/>		
The condom caught the male's pubic hair .....		<input type="checkbox"/>	<input type="checkbox"/>		
The condom made noise during intercourse .....		<input type="checkbox"/>	<input type="checkbox"/>		
The male lost his erection during intercourse .....		<input type="checkbox"/>	<input type="checkbox"/>		
We used the condom for anal intercourse .....		<input type="checkbox"/>	<input type="checkbox"/>		
<b>12. Did ejaculation occur while wearing this study condom?</b>					
<input type="checkbox"/> Yes					
<input type="checkbox"/> No. Ejaculated without a study condom					
<input type="checkbox"/> No. Ejaculation did not occur with this act of intercourse					
<b>13. Did you do the following during withdrawal?</b> (Check Yes or No for each.)		Yes	No		
I held on to the ring of condom .....		<input type="checkbox"/>	<input type="checkbox"/>		
Withdrawal while penis was still erect .....		<input type="checkbox"/>	<input type="checkbox"/>		
<b>14. Do you think that semen may have leaked from the condom?</b>					
<input type="checkbox"/> No					
<input type="checkbox"/> Yes, When the condom broke					
<input type="checkbox"/> Yes, When the condom slipped <u>off</u> the penis					
<input type="checkbox"/> Yes, When the condom slipped <u>along</u> the penis					
<input type="checkbox"/> Yes, At another time, describe: .....					
<input type="checkbox"/> Yes, Don't know when					
<b>15. How long did vaginal intercourse last while wearing this condom?</b>					
		minutes			
<b>16. Please rate the following.</b> (Check one box per line.)					
		<b>MALE ANSWERS</b>			
		Excellent	Good	Fair	Poor
Stimulation during intercourse .....		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Condom lubricant .....		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Overall lubrication during intercourse .....		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>17. Did you experience any discomfort that started while using this condom?</b>		<input type="checkbox"/> No: Skip to Q#18		<input type="checkbox"/> Yes	
<b>17a. What ONE discomfort best describes the type?</b> (Check ONE if most severe)		<input type="checkbox"/> Burning		<input type="checkbox"/> Genital itching	
		<input type="checkbox"/> Irritation		<input type="checkbox"/> Genital rash	
		<input type="checkbox"/> Constriction		<input type="checkbox"/> Diminished sensitivity	
		<input type="checkbox"/> Dryness			
		<input type="checkbox"/> Other, describe: .....			
<b>17b. How severe was the discomfort?</b>		<input type="checkbox"/> Mild		<input type="checkbox"/> Moderate	
				<input type="checkbox"/> Severe	
<b>17c. How long did the discomfort last?</b>		<input type="checkbox"/> Only while wearing the condom		<input type="checkbox"/> Only while in contact with the condom	
		<input type="checkbox"/> 1 - 10 minutes after the condom was removed		<input type="checkbox"/> 1 - 10 minutes after the condom was removed	
		<input type="checkbox"/> More than 10 minutes but less than 1 hour after		<input type="checkbox"/> More than 10 minutes but less than 1 hour after	
		<input type="checkbox"/> One hour or more after condom was removed		<input type="checkbox"/> One hour or more after condom was removed	
<b>17d. Do you know what might have caused the discomfort?</b>		<input type="checkbox"/> No		<input type="checkbox"/> No	
		<input type="checkbox"/> Yes, describe: .....		<input type="checkbox"/> Yes, describe: .....	
<b>17e. Did you do anything medically to treat the discomfort?</b>		<input type="checkbox"/> No		<input type="checkbox"/> No	
		<input type="checkbox"/> Yes, describe: .....		<input type="checkbox"/> Yes, describe: .....	
<b>18. Who filled out this Condom Report?</b>		<input type="checkbox"/> Man		<input type="checkbox"/> Woman	
				<input type="checkbox"/> Both partners together	
<b>19. Additional comments:</b>					

EXAMPLE 2 Three-page CRF for individual condom use, submitted by FHI.

BSCUQ1

<p><b>FAMILY HEALTH INTERNATIONAL</b> A Comparative Assessment of Synthetic Condom and Natural Rubber Latex Condom: Failure Modes <b>CONDOM USE QUESTIONNAIRE</b></p>		
<p>1. Centre number: <input type="text"/><input type="text"/><input type="text"/>      2. Study number: <input type="text" value="9"/><input type="text" value="6"/><input type="text" value="0"/><input type="text" value="9"/>      3. Couple number: <input type="text"/><input type="text"/><input type="text"/><input type="text"/></p> <p>4. Condom type: <input type="text"/></p> <p>1 = Natural Rubber Latex 2 = Synthetic</p>		
<p><b>CONDOM USE DATA</b></p> <p>Please complete one of these questionnaires for each condom package opened. For the following items, please circle the response which best answers the question in some cases, you might be instructed to select more than one answer. Please notice that some questions instruct you to "skip to" other questions based on your response. In these cases, do not answer any of the questions between the original one and the one to which you were instructed to skip.</p>		
<p>5. Condom number. Circle one. Do not use more than 4 condoms for intercourse.</p> <p>1      2      3      4      5      6</p> <p>6. Date condom opened      <input type="text"/><input type="text"/>      <input type="text"/><input type="text"/>      <input type="text"/><input type="text"/><input type="text"/><input type="text"/> Month      Day      Year</p> <p>7. Was the condom stored in a cool, dry place? Circle one, 0 = No      1 = Yes</p>		<p>8. Did the condom break or tear <u>before putting it on the penis</u>? Circle one.</p> <p>0 = No 1 = Yes, <b>while</b> opening the package 2 = Yes, <b>after</b> opening, at the condom tip 3 = Yes, <b>after</b> opening, along the condom shaft 4 = Yes, <b>after</b> opening, at the condom opening 5 = Yes, <b>after</b> opening, at other location</p>
<p><u>If the condom broke before putting it on, do not answer any more questions.</u> If the condom did not break and you tried to put it on, answer the following questions.</p>		
<p>9. Did you use the provided lubricant <u>before putting on the condom</u>? <i>Circle all that apply.</i></p> <p>0 = No 1 = Yes, on the inside of the condom 2 = Yes, on the outside of the condom 3 = Yes, inside the vagina 4 = Yes, inside the anus</p> <p>10. Did you use another type of lubricant before putting on the condom? <i>Circle all that apply.</i></p> <p>0 = No 1 = Yes, on the inside of the condom 2 = Yes, on the outside of the condom 3 = Yes, inside the vagina 4 = Yes, inside the anus <i>If yes, specify lubricant type</i> _____</p> <p>11. Was there any genital contact before putting on the condom? <i>Circle one.</i></p> <p>0 = No 1 = Yes, but no vaginal or anal penetration 2 = Yes, with vaginal or anal penetration</p>		<p>12. Who tried to put on the condom? <i>Circle one.</i></p> <p>1 = female      2 = male      3 = both</p> <p>13. Was the penis erect before putting on or trying to put on the condom? <i>Circle one.</i></p> <p>0 = No      1 = Yes</p> <p>14. Was the condom unrolled before putting on or trying to put the condom on the penis? <i>Circle one.</i></p> <p>0 = No      1 = Yes</p> <p>15. Were you able to put the condom on the penis? <i>Circle one.</i></p> <p>0 = No 1 = Yes, the condom went on easily 2 = Yes, but the condom did not go easily.</p> <p>16. Did the condom break <u>while putting it on or trying to put it on</u>, but <b>before</b> intercourse? <i>Circle one.</i></p> <p>0 = No 1 = Yes, at the condom tip 2 = Yes, along the condom shaft 3 = Yes, at the condom opening 4 = Yes, other</p>
<p><u>IF THE CONDOM BROKE WHILE PUTTING IT ON OR TRYING TO PUT IT ON, SKIP TO QUESTION 33.</u></p>		

**FAMILY HEALTH INTERNATIONAL**  
A Comparative Assessment of Synthetic Condom and Natural Rubber Latex Condom:  
Failure Modes  
**CONDOM USE QUESTIONNAIRE**

STUDY IDENTIFICATION			
Centre number:	<div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block;"></div> <div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block;"></div> <div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block;"></div>	Study number:	<div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block; text-align: center;">9</div> <div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block; text-align: center;">6</div> <div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block; text-align: center;">0</div> <div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block; text-align: center;">9</div>
Condom type:	<div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block;"></div>	Couple Number:	<div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block;"></div> <div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block;"></div> <div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block;"></div> <div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block;"></div>
1 = Natural rubber latex 2 = Synthetic			
Answer the following questions if you were able to put the condom on the penis without it breaking.			
17. Was the condom pulled/rolled down the shaft of the penis? <i>Circle one.</i>  0 = No                                      1 = Yes  18. After the condom was put on, did it cover the entire penis? <i>Circle one.</i>  0 = No                                      1 = Yes  19. Did you use the provided lubricant <u>after putting on the condom, but before intercourse</u> ? <i>Circle all that apply.</i>  0 = No 1 = Yes, on the outside of the condom 2 = Yes, inside the vagina 3 = Yes, inside the anus	20. Did you use another type of lubricant <u>after putting on the condom, but before intercourse</u> ? <i>Circle all that apply.</i>  0 = No 1 = Yes, on the outside of the condom 2 = Yes, inside the vagina 3 = Yes, inside the anus If yes, specify lubricant type _____  21. Did the condom break <u>after putting it on, but before intercourse</u> ? <i>Circle one.</i>  0 = No 1 = Yes, at the condom tip 2 = Yes, along the condom shaft 3 = Yes, at the condom opening 4 = Yes, other <div style="float: right; text-align: right;">             } <i>if yes, skip to Question 33</i> </div>		
<b><u>If you did not have intercourse wearing this condom, skip to Question 33.</u></b> otherwise answer the following questions.			
22. Did you use the provided lubricant <u>during sex</u> ? <i>Circle all that apply.</i>  0 = No 1 = Yes, on the penis 2 = Yes, inside the vagina 3 = Yes, inside the anus  23. Did you use another type of lubricant <u>during sex</u> ? <i>Circle all that apply.</i>  0 = No 1 = Yes, on the penis 2 = Yes, inside the vagina 3 = yes inside the anus If yes, specify lubricant type _____  24. While wearing this condom in which of the following did you engage? <i>Circle all that apply.</i>  1 = front entry vaginal sex 2 = rear entry vaginal sex 3 = other vaginal sex 4 = anal sex 5 = oral sex on male partner	25. Did the condom break during sex or while removing the condom from the penis? <i>Circle one.</i>  0 = No 1 = Yes, during front entry vaginal sex 2 = Yes, during rear entry vaginal sex 3 = Yes, during other type of vaginal sex 4 = Yes, during withdrawal from the vagina 5 = Yes, during anal sex 6 = Yes, during withdrawal from the anus 7 = Yes, during oral sex on the male partner 8 = Yes, while taking condom off the penis 9 = Yes, other or don't know when  26. Where did the condom break? <i>Circle one.</i>  0 = did not break 1 = at the tip of the condom 2 = along the shaft of the condom 3 = at the opening of the condom 4 = other  27. How many minutes was the condom worn during vaginal intercourse <div style="float: right;"> <div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block;"></div> <div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block;"></div> <div style="border: 1px solid black; width: 20px; height: 20px; display: inline-block;"></div> </div>		

FAMILY HEALTH INTERNATIONAL  
A Company Assessment of a Plastic Condom and a Latex Condom:  
Failure Modes  
CONDOM USE QUESTIONNAIRE

STUDY IDENTIFICATION

Centre number:

Study number:

9

6

0

9

Couple number:

Condom type:

1 = Latex  
2 = Plastic

Answer the following questions ONLY IF the condom was used for vaginal intercourse.  
If the condom was NOT used for vaginal intercourse, skip to Question 33.

<div>28. Did the male partner ejaculate while wearing the condom? <i>Circle one.</i></div> <div><div>0 = No</div><div>2 = Yes, during vaginal sex</div><div>1 = Yes, during anal sex</div><div>3 = Yes, during other sex</div></div> <div>29. Did the condom ring slip from the base of the penis during vaginal intercourse? <i>Circle one.</i></div> <div><div>0 = No</div><div>1 = Yes, it slipped completely off the penis</div><div>2 = Yes, it slipped but not completely off the penis</div><div>3 = don't know not sure</div></div>	<div>30. Was the penis still hard when it was pulled out of the vagina? <i>Circle one.</i></div> <div><div>0 = No</div><div>1 = Yes</div></div> <div>31. Did you hold on to the base of the condom during withdrawal from the vagina? <i>Circle one.</i></div> <div><div>0 = No</div><div>1 = Yes</div></div> <div>32. Did the condom ring slip from the base of the penis during withdrawal from the vagina? <i>Circle one.</i></div> <div><div>0 = No</div><div>1 = Yes, it slipped completely off the penis</div><div>2 = Yes, it slipped but not completely off the penis</div><div>3 = don't know not sure</div></div>
---	---

33. Did one or both partners drink alcohol within one hour of using the condom?

0 = No

1 = Yes, only male partner

2 = Yes, only female partner

3 = Yes, both partner

34. Did either of you experience genital burning, irritation, rash, itching, pain or other medical event that began while using this condom?  
*Circle one.*

0 = No

1 = Yes, only male partner

2 = Yes, only female partner

3 = Yes, both partner

} If 1, 2, or 3, complete *Medical Event form*

Initials of person reviewing form: \_\_\_\_\_ Date form reviewed: \_\_\_\_\_

30

© ISO 2017 – All rights reserved

EXAMPLE 3 One-page CRF for individual condom use, submitted by Sagami-France.

Ref number: 

SHORT QUESTIONNAIRE

1. Use condom ("A" or "B")

2. Type of intercourse (Please tick the cases below, e.g. oral followed by vaginal, please mark 1 for oral and 2 for vaginal, if only one type, please tick below)

Oral | Vaginal | Anal

Does the question during intercourse (e.g. you do not know the type, you do not know the type)

1 How long was the foreplay when using this condom? (min)

No foreplay

0-5 min

5-10 min

10-20 min

20-30 min

Longer

2 How long was the intercourse when using this condom? (min)

0-5 min

5-10 min

10-20 min

20-30 min

Longer

3 Were you ready when using the condom if woman is dry this can lead to breakage? (Please tick below)

YES

NO

4 Did condom break? (Please tick below)

YES

NO

If YES, go to question 5, if NO, go to 8

5 Where did it break? (Please tick below)

Test seal

Lead

Body

6 When did it break? (Please tick below)

Before out of package

During foreplay

During intercourse

Normal after intercourse

7 Which type of break? (Please tick below)

Small hole

Split

Leak

8 Could you explain why the condom broke?

9 Did the condom slip? (Please tick below)

YES

NO

If YES, go to question 10, if NO, go to 14

10 When did the condom slip? (Please tick below)

During foreplay

On the withdrawal

11 How far did the penis did the condom slip? (Please tick below)

Right off the penis

1/2 down the shaft of the penis

3/4 down the shaft of the penis

5/6 down the shaft of the penis

12 Did you hold the condom when withdrawing? (Please tick below)

YES

NO

13 Did any semen enter the vagina or urethra? (Please tick below)

YES

NO

14 It is normal to have various sensations on and around the penis and vagina, especially when using gelic lubricating but did you feel something different (are you do not feel with your usual condoms)? (Please tick below, multiple answers are accepted)

Nothing different

Yes

Burning sensation

Prickling

15 What did you most notice about this condom? (Please tick below, multiple answers are accepted)

Nothing at all

Natural feeling

Thinness

On the loss

Comfort

Sensation

Annex G  
(informative)

CRF — Adverse event (sample)

Time Began: \_\_\_\_\_ Time Ended: \_\_\_\_\_ Interview Length: \_\_\_\_\_

Interviewer’s Initials: \_\_\_\_\_ Date: \_\_\_\_\_

- **If an individual reaches you directly:** “What is your name? \_\_\_\_\_ (Name). I would like to ask you some questions about your experience with the test products. It will take around 5 minutes. Is this a good time for you to discuss it now?” (If not, reschedule day \_\_\_\_\_ time \_\_\_\_\_ - is there a number where I may reach you? \_\_\_\_\_)
- **If an individual left you a message:** “May I speak to \_\_\_\_\_ (Name)? This is \_\_\_\_\_ from \_\_\_\_\_. You are participating in a study with the Group. You had called and left a message about a reaction to one of our test products. I would like to ask you some questions about your experience with the test products. It will take around 5 minutes. Is this a good time for you to discuss it now?” (If not, reschedule day \_\_\_\_\_ time \_\_\_\_\_ - is there a number where I may reach you? \_\_\_\_\_)

1. “What is the product that you were using when you experienced your reaction?”  
\_\_\_\_\_
2. “Would you describe what happened?” (Circle symptoms from no. 3 as they are mentioned.)  
\_\_\_\_\_

3. “Would you say that your _____ (symptom) was mild, moderate or severe?”	Subject’s Assessment		
	Mild	Moderate	Severe
Itching			
Burning/stinging			
Redness			
Bumps			
Other: _____			
Other: _____			

4. “How soon after you put the product on did you first experience this reaction?”  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_
5. “How long did your reaction last?” \_\_\_\_\_
6. “Have you seen a doctor?” \_\_\_\_\_ yes \_\_\_\_\_ no (skip to 10)
7. “May we contact your doctor?” \_\_\_\_\_ yes \_\_\_\_\_ no (skip to 10)
8. “What is your doctor’s name?” \_\_\_\_\_
9. “What is your doctor’s telephone number?” (\_\_\_\_\_) \_\_\_\_\_ - \_\_\_\_\_

10. "Have you experienced similar reactions with similar products?" \_\_\_\_\_ yes \_\_\_\_\_ no

"Which products?"

-----

Example interviewer response:

"I recommend that you stop using the product if you have not already done so and do not use any additional test products we gave you. If you wish to see a physician and have not already done so, and your physician determines that your reaction is product-related, please provide us with a copy of your doctor's note with his name and office number so that we may review it for reimbursement. Call me back if you have any problems. Thank you for your time and patience."

Annex H  
(informative)

Protocol for evaluation of returned used condoms

H.1 General

The following is a suggested protocol for in-house evaluation of condoms returned by study subjects after a tear or break during use. [Figure H.2](#) and [Figure H.3](#) give detailed step-by-step procedures.

H.2 Disinfection of returned used condoms


**WARNING** — This study requires direct contact with condoms that might be contaminated with infectious microbes. To reduce the risk of an infectious accident, it is strongly recommended that the operator wear surgical or exam gloves, safety glasses and a laboratory coat whenever handling the used condom.

**H.2.1** Remove the returned used condom (“the sample”) from its plastic shipping bag.

**H.2.2** Examine the sample and record observations, if any.

**H.2.3** If the sample is not fully unrolled, mark its unrolled part within oil-based marker. If the sample is wet and not possible to mark, then photograph it. Then, unroll the sample to the rim (see Note).

**NOTE** In [Figure H.1](#), the mark illustrates the length of the sample unrolled onto the user’s penis. If the length is extremely short, the user might not have unrolled the condom to the base of the penis before use. In that case, the risk of slippage might increase.




Key

- 1 marking
- 2 length of the sample unrolled onto the penis

Figure H.1 — Marking the returned condom

**H.2.4** Prepare a disinfection solution (see [Figure H.2](#)).



**Figure H.2 — Preparation of the disinfectant solution (4,5 % sodium hypochlorite)**


**Instructions:**


- a) The commercial solution can be stored for 6 months, keeping away from the heat and direct light.
- b) The dilutes 4,5 % solution, if free from protein, can be stored for 1 week at room temperature.
- c) Properly disposed of diluted solution after its use to disinfect a condom sample.

Make freshly prepared diluted solution for the next set of used condoms.

**H.2.5** Following the step-wise procedures given in [Figure H.3](#), prepare the condom for evaluation.

**NOTE** There are alternate methods for disinfecting the condom samples. To disinfect by boiling, about 15 min might be required. For chemical disinfection, be sure to use a chemical agent that does not adversely affect the physical properties of the condoms. In any case, continue to use exam or surgical gloves.





NOTE Steps 1 and 2: Administrative Department. Step 3 to 19: Quality Laboratory.

**Figure H.3 — Returned condoms, procedure for condom decontamination**

**H.2.6** Rinse the disinfected sample with water and apply a suitable powder, e.g. silica, to absorb moisture.

**H.3 Observation**

**H.3.1** Place the sample on a mandrel of similar diameter.

NOTE If a condom manufacturer does the observations, then it is best done using one of the condom mandrels from the dipping process.


**H.3.2** Make sketches or take photos of the sample especially the torn parts.

**H.3.3** Record observations (see Note).

NOTE It is helpful to observe the torn parts and find the starting point of the tear.

H.3.3.1 Examples of observations, how to find the starting point.


In the image below,  and  indicate the starting point of the tear. The red arrow indicates a gap.





**Circular tear**  
The starting point of the circular tear is often determined at the diagonal line, in the highlighted area.




If a gap is observed on the circular tear portion, the starting point of the tear is often determined at the opposite side of the gap.



**Split tear**  
The starting point of the tear is often determined at the opposite side (to that of a circular tear) in the highlighted area.




**V shape tear**  
The starting point is often found at the close end of V.



**Crack tear**  
The starting point is often found at the part where condition of the film is not normal.




### H.3.3.2 Examples of the starting point/tear.



#### Transformation

The film elongated and tore due to the load exceeding the strength limit. Possible reasons are as follows.

- The strength of the film itself was poor.
- The condom did not fit the penis well and adhered too tightly to the side of the penis.
- Air was present between the condom and the penis and the condom burst during the sexual intercourse.
- When taking out the condom, film was damaged by the pouch.



#### Scratch

The hard item scratches the film. During the sexual intercourse, the condom was torn at the scratched part. Possible reasons are as follows.

- The condom is already scratched during the production process.
- The user scratches the condom with her/his nails or rings.

## H.4 Tensile measurements

After making the visual observations described above, the Quality Laboratory should conduct tensile testing of the sample to determine whether it has acceptable strength. Using a test specimen taken from the sample, either ring or dumbbell, the Quality Laboratory should follow appropriate standards or published procedures for tensile testing. For example, for dumbbell specimens, you could use the method described in Reference [22]. However, if the country where the sample was used already has a standard for tensile testing of condoms, then typically one would apply that national standard.

**WARNING — Some methods for disinfection might adversely affect the physical properties of a condom and lead to unexpectedly poor results from tensile testing. Consider this when developing your in-house protocol.**

## H.5 Records

Record the following items:

- sketches and/or photos of the sample;
- any observations reported by the study couple;
- results of tensile testing, if possible;
- any conclusions on presumed causes of the tear based on evidence from the above three items, a) to c).

NOTE See Reference [23] for the description of “blunt puncture”.

**H.6 Conclusion**

It is often difficult to determine the underlying cause of a condom tear based only on a single sample of a torn condom. Therefore, the Quality Laboratory should re-evaluate all torn samples after the study is complete and determine if there are any trends.

## Bibliography

### General principles

- [1] ASTM D7661, *Standard test method for determining compatibility of personal lubricants with natural rubber latex condoms*
- [2] STEINER M., TRUSSELL J., GLOVER L., JOANIS C., SPRUYT A., DORFLINGER L. Standardized protocols for condom breakage and slippage trials: a proposal. *Am. J. Public Health.* 1994, **84** (12) pp. 1897–1900
- [3] BLACKWELDER W.C. Proving the null hypothesis in clinical trials. *Control. Clin. Trials.* 1982, **3** (4) pp. 345–353
- [4] *Computerized systems used in clinical investigations — Guidance for industry* (US Food & Drug, Might 2007). <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070266.pdf>
- [5] LIANG K.-Y., & ZEGER S.L. Longitudinal data analysis using generalized linear models. *Biometrika.* 1986, **73** (1) pp. 13–22
- [6] TAYLOR D.J., & DOMINIK R.C. Non-inferiority testing in crossover trials with correlated binary outcomes and small event proportions with applications to the analysis of condom failure data. *J. Biopharm. Stat.* 1999, **9** (2) pp. 367–377
- [7] STEINER M.J., LOVVORN A.E., SCHULZ K.F. Bogus participation in clinical trials. *JAMA.* 2001, **285** (3) p. 293
- [8] TAYLOR D.J. Issues in the design, analysis, and interpretation of condom functionality studies. *Contraception.* 2009, **80** (3) pp. 237–244
- [9] *Good clinical practice* (ICH-E6) and *Statistical principles for clinical trials* (ICH-E9) available at <http://www.ich.org>
- [10] SCHULZ K.F., ALTMAN D.G., MOHER D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ.* 2010, **340** p. c332
- [11] *Research ethics committees: Basic concepts for capacity-building*; WHO 2009. [http://www.who.int/eth/Ethics\\_basic\\_concepts\\_ENG.pdf](http://www.who.int/eth/Ethics_basic_concepts_ENG.pdf)
- [12] *Ethical challenges in study design and informed consent for health research in resource-poor settings*/ Patricia A. Marshall. “TDR/SDR/SEB/ST/07.1”; WHO 2007 <http://www.who.int/tdr/publications/tdr-research-publications/ethical-challenges-study-design/en/>

### Condom studies, selection and recall bias

- [13] GRAHAM C.A., CATANIA J.A., BRAND R., DUONG T., CANCHOLA J.A. Recalling sexual behavior: a methodological analysis of memory recall bias via interview using the diary as the gold standard. *J. Sex Res.* 2003, **40** (4) pp. 325–332
- [14] MINNIS A.M., STEINER M.J., GALLO M.F., WARNER L., HOBBS M.M., VAN DER STRATEN A. Biomarker validation of reports of recent sexual activity: results of a randomized controlled study in Zimbabwe. *Am. J. Epidemiol.* 2009, **170** (7) pp. 918–924
- [15] SCHRODER K.E., CAREY M.P., VANABLE P.A. Methodological challenges in research on sexual risk behavior: II. Accuracy of self-reports. *Ann. Behav. Med.* 2003, **26** (2) pp. 104–123

### Condom studies of breakage and slippage, results

The following is a partial list of published articles in peer-reviewed journals describing good quality studies designed to measure condom slippage and breakage rates.

- [16] CALLAHAN M., MAUCK C., TAYLOR D., FREZIERES R., WALSH T., MARTENS M. Comparative evaluation of three Tactylon(TM) condoms and a latex condom during vaginal intercourse: breakage and slippage. *Contraception*. 2000, **61** (3) pp. 205–215
- [17] COOK L., NANDA K., TAYLOR D. Randomized crossover trial comparing the eZ.on plastic condom and a latex condom. *Contraception*. 2001, **63** (1) pp. 25–31
- [18] FREZIERES R.G., WALSH T.L., NELSON A.L., CLARK V.A., COULSON A.H. Breakage and acceptability of a polyurethane condom: a randomized, controlled study. *Fam. Plann. Perspect.* 1998, **30** (2) pp. 73–78
- [19] FREZIERES R.G., WALSH T.L., NELSON A.L., CLARK V.A., COULSON A.H. Evaluation of the efficacy of a polyurethane condom: results from a randomized, controlled clinical trial. *Fam. Plann. Perspect.* 1999, **31** (2) pp. 81–87
- [20] POTTER W.D., & de VILLEMEUR M. Clinical breakage, slippage and acceptability of a new commercial polyurethane condom: a randomized, controlled study. *Contraception*. 2003, **68** (1) pp. 39–45
- [21] STEINER M.J., DOMINIK R., ROUNTREE R.W., NANDA K., DORFLINGER L.J. Contraceptive effectiveness of a polyurethane condom and a latex condom: a randomized controlled trial. *Obstet. Gynecol.* 2003, **101** (3) pp. 539–547

### Evaluation of broken condoms

- [22] GEROFI J., SHELLEY G., DONOVAN B. A study of the relationship between tensile testing of condoms and breakage in use. *Contraception*. 1991, **43** (2) pp. 177–178
- [23] WHITE N.D., HILL D.M., BODEMEIER S. Male condoms that break in use do so mostly by a “blunt puncture” mechanism. *Contraception*. 2008, **77** (5) pp. 360–365

### Relevant ISO standards for guidance

- [24] ISO 4074:2015, *Natural rubber latex male condoms — Requirements and test methods*
- [25] ISO 13485, *Medical devices — Quality management systems — Requirements for regulatory purposes*
- [26] ISO 14155, *Clinical investigation of medical devices for human subjects — Good clinical practice*
- [27] ISO 16037, *Rubber condoms for clinical trials — Measurement of physical properties*
- [28] ISO 23409:2011, *Male condoms — Requirements and test methods for condoms made from synthetic materials*



# British Standards Institution (BSI)

BSI is the national body responsible for preparing British Standards and other standards-related publications, information and services.

BSI is incorporated by Royal Charter. British Standards and other standardization products are published by BSI Standards Limited.

## About us

We bring together business, industry, government, consumers, innovators and others to shape their combined experience and expertise into standards-based solutions.

The knowledge embodied in our standards has been carefully assembled in a dependable format and refined through our open consultation process. Organizations of all sizes and across all sectors choose standards to help them achieve their goals.

## Information on standards

We can provide you with the knowledge that your organization needs to succeed. Find out more about British Standards by visiting our website at [bsigroup.com/standards](https://bsigroup.com/standards) or contacting our Customer Services team or Knowledge Centre.

## Buying standards

You can buy and download PDF versions of BSI publications, including British and adopted European and international standards, through our website at [bsigroup.com/shop](https://bsigroup.com/shop), where hard copies can also be purchased.

If you need international and foreign standards from other Standards Development Organizations, hard copies can be ordered from our Customer Services team.

## Copyright in BSI publications

All the content in BSI publications, including British Standards, is the property of and copyrighted by BSI or some person or entity that owns copyright in the information used (such as the international standardization bodies) and has formally licensed such information to BSI for commercial publication and use.

Save for the provisions below, you may not transfer, share or disseminate any portion of the standard to any other person. You may not adapt, distribute, commercially exploit, or publicly display the standard or any portion thereof in any manner whatsoever without BSI's prior written consent.

## Storing and using standards

Standards purchased in soft copy format:

- A British Standard purchased in soft copy format is licensed to a sole named user for personal or internal company use only.
- The standard may be stored on more than 1 device provided that it is accessible by the sole named user only and that only 1 copy is accessed at any one time.
- A single paper copy may be printed for personal or internal company use only.

Standards purchased in hard copy format:

- A British Standard purchased in hard copy format is for personal or internal company use only.
- It may not be further reproduced – in any format – to create an additional copy. This includes scanning of the document.

If you need more than 1 copy of the document, or if you wish to share the document on an internal network, you can save money by choosing a subscription product (see 'Subscriptions').

## Reproducing extracts

For permission to reproduce content from BSI publications contact the BSI Copyright & Licensing team.

## Subscriptions

Our range of subscription services are designed to make using standards easier for you. For further information on our subscription products go to [bsigroup.com/subscriptions](https://bsigroup.com/subscriptions).

With **British Standards Online (BSOL)** you'll have instant access to over 55,000 British and adopted European and international standards from your desktop. It's available 24/7 and is refreshed daily so you'll always be up to date.

You can keep in touch with standards developments and receive substantial discounts on the purchase price of standards, both in single copy and subscription format, by becoming a **BSI Subscribing Member**.

**PLUS** is an updating service exclusive to BSI Subscribing Members. You will automatically receive the latest hard copy of your standards when they're revised or replaced.

To find out more about becoming a BSI Subscribing Member and the benefits of membership, please visit [bsigroup.com/shop](https://bsigroup.com/shop).

With a **Multi-User Network Licence (MUNL)** you are able to host standards publications on your intranet. Licences can cover as few or as many users as you wish. With updates supplied as soon as they're available, you can be sure your documentation is current. For further information, email [subscriptions@bsigroup.com](mailto:subscriptions@bsigroup.com).

## Revisions

Our British Standards and other publications are updated by amendment or revision.

We continually improve the quality of our products and services to benefit your business. If you find an inaccuracy or ambiguity within a British Standard or other BSI publication please inform the Knowledge Centre.

## Useful Contacts

### Customer Services

**Tel:** +44 345 086 9001

**Email (orders):** [orders@bsigroup.com](mailto:orders@bsigroup.com)

**Email (enquiries):** [cservices@bsigroup.com](mailto:cservices@bsigroup.com)

### Subscriptions

**Tel:** +44 345 086 9001

**Email:** [subscriptions@bsigroup.com](mailto:subscriptions@bsigroup.com)

### Knowledge Centre

**Tel:** +44 20 8996 7004

**Email:** [knowledgecentre@bsigroup.com](mailto:knowledgecentre@bsigroup.com)

### Copyright & Licensing

**Tel:** +44 20 8996 7070

**Email:** [copyright@bsigroup.com](mailto:copyright@bsigroup.com)

### BSI Group Headquarters

389 Chiswick High Road London W4 4AL UK